
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4BAF98AF429D305BAF900033B9B1F.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="diametsyn">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374370/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Diabetology &amp; Metabolic Syndrome">
<meta name="citation_title" content="GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis">
<meta name="citation_author" content="Mohamed Mohsen Helal">
<meta name="citation_author_institution" content="Faculty of Medicine, Zagazig University, Zagazig, Egypt">
<meta name="citation_author" content="Hala AbouShawareb">
<meta name="citation_author_institution" content="Faculty of Medicine, Mansoura University, Mansoura, Egypt">
<meta name="citation_author" content="Omarfayez Hussein Abbas">
<meta name="citation_author_institution" content="Faculty of Medicine, Al-Azhar University, Cairo, Egypt">
<meta name="citation_author" content="Roaa Haddad">
<meta name="citation_author_institution" content="Faculty of Medicine, October 6 University, Giza, Egypt">
<meta name="citation_author" content="Youmna Zain">
<meta name="citation_author_institution" content="Faculty of Medicine, Tanta University, Tanta, Egypt">
<meta name="citation_author" content="Ahmed S A Osman">
<meta name="citation_author_institution" content="Faculty of Medicine, Minia University, Minia, Egypt">
<meta name="citation_author" content="Amr K Hassan">
<meta name="citation_author_institution" content="Department of Ophthalmology, School of Medicine, University of California, Irvine, CA USA">
<meta name="citation_author_institution" content="Medical Research Group of Egypt, Negida Academy, Arlington, MA USA">
<meta name="citation_publication_date" content="2025 Aug 23">
<meta name="citation_volume" content="17">
<meta name="citation_firstpage" content="352">
<meta name="citation_doi" content="10.1186/s13098-025-01888-1">
<meta name="citation_pmid" content="40849485">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374370/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374370/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374370/pdf/13098_2025_Article_1888.pdf">
<meta name="description" content="Previous studies have demonstrated an increased risk of developing Parkinson’s disease (PD) in patients with type 2 diabetes mellitus (T2DM), as well as more severe and rapid motor and non-motor deterioration in diabetic PD patients compared to ...">
<meta name="og:title" content="GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Previous studies have demonstrated an increased risk of developing Parkinson’s disease (PD) in patients with type 2 diabetes mellitus (T2DM), as well as more severe and rapid motor and non-motor deterioration in diabetic PD patients compared to ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374370/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374370">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s13098-025-01888-1"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/13098_2025_Article_1888.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374370%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374370/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374370/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374370/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-diametsyn.png" alt="Diabetology &amp; Metabolic Syndrome logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Diabetology &amp; Metabolic Syndrome" title="Link to Diabetology &amp; Metabolic Syndrome" shape="default" href="https://dmsjournal.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Diabetol Metab Syndr</button></div>. 2025 Aug 23;17:352. doi: <a href="https://doi.org/10.1186/s13098-025-01888-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s13098-025-01888-1</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Diabetol%20Metab%20Syndr%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetol%20Metab%20Syndr%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Diabetol%20Metab%20Syndr%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Diabetol%20Metab%20Syndr%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Helal%20MM%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Mohamed Mohsen Helal</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Mohamed Mohsen Helal</span></h3>
<div class="p">
<sup>1</sup>Faculty of Medicine, Zagazig University, Zagazig, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Helal%20MM%22%5BAuthor%5D" class="usa-link"><span class="name western">Mohamed Mohsen Helal</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22AbouShawareb%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Hala AbouShawareb</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Hala AbouShawareb</span></h3>
<div class="p">
<sup>2</sup>Faculty of Medicine, Mansoura University, Mansoura, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22AbouShawareb%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hala AbouShawareb</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abbas%20OH%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Omarfayez Hussein Abbas</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Omarfayez Hussein Abbas</span></h3>
<div class="p">
<sup>3</sup>Faculty of Medicine, Al-Azhar University, Cairo, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abbas%20OH%22%5BAuthor%5D" class="usa-link"><span class="name western">Omarfayez Hussein Abbas</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Haddad%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Roaa Haddad</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Roaa Haddad</span></h3>
<div class="p">
<sup>4</sup>Faculty of Medicine, October 6 University, Giza, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Haddad%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Roaa Haddad</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zain%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Youmna Zain</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Youmna Zain</span></h3>
<div class="p">
<sup>5</sup>Faculty of Medicine, Tanta University, Tanta, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zain%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Youmna Zain</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Osman%20ASA%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Ahmed S A Osman</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Ahmed S A Osman</span></h3>
<div class="p">
<sup>6</sup>Faculty of Medicine, Minia University, Minia, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Osman%20ASA%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmed S A Osman</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hassan%20AK%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Amr K Hassan</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Amr K Hassan</span></h3>
<div class="p">
<sup>7</sup>Department of Ophthalmology, School of Medicine, University of California, Irvine, CA USA </div>
<div class="p">
<sup>8</sup>Medical Research Group of Egypt, Negida Academy, Arlington, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hassan%20AK%22%5BAuthor%5D" class="usa-link"><span class="name western">Amr K Hassan</span></a>
</div>
</div>
<sup>7,</sup><sup>8</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Faculty of Medicine, Zagazig University, Zagazig, Egypt </div>
<div id="Aff2">
<sup>2</sup>Faculty of Medicine, Mansoura University, Mansoura, Egypt </div>
<div id="Aff3">
<sup>3</sup>Faculty of Medicine, Al-Azhar University, Cairo, Egypt </div>
<div id="Aff4">
<sup>4</sup>Faculty of Medicine, October 6 University, Giza, Egypt </div>
<div id="Aff5">
<sup>5</sup>Faculty of Medicine, Tanta University, Tanta, Egypt </div>
<div id="Aff6">
<sup>6</sup>Faculty of Medicine, Minia University, Minia, Egypt </div>
<div id="Aff7">
<sup>7</sup>Department of Ophthalmology, School of Medicine, University of California, Irvine, CA USA </div>
<div id="Aff8">
<sup>8</sup>Medical Research Group of Egypt, Negida Academy, Arlington, MA USA </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 14; Accepted 2025 Jul 27; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374370  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40849485/" class="usa-link">40849485</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Previous studies have demonstrated an increased risk of developing Parkinson’s disease (PD) in patients with type 2 diabetes mellitus (T2DM), as well as more severe and rapid motor and non-motor deterioration in diabetic PD patients compared to their non-diabetic counterparts. Additional research has suggested that diabetic subjects treated with glucagon-like peptide-1 (GLP-1) receptor agonists exhibit a reduced incidence of PD compared to those receiving other anti-diabetic medications. GLP-1 receptor agonists are FDA-approved therapies for T2DM, and recent studies have explored their potential as repurposed treatments for neurodegenerative diseases, including PD, AD, and ALS, as well as cerebrovascular disorders. This systematic review aims to assess the available literature on the efficacy and safety profiles of GLP-1 receptor agonists in PD management. A comprehensive search of PubMed, Scopus, CENTRAL, Web of Science, Embase, and ClinicalTrials.gov was conducted to identify relevant studies. The primary outcomes of this review include motor impairment in PD, as assessed by MDS-UPDRS Part III, as well as motor complications (Part IV) and motor experiences of daily living (Part II), and the incidence of gastrointestinal and systemic side effects. Meta-analysis showed that GLP-1 receptor agonists significantly improved motor function, as reflected by MDS-UPDRS Part III scores in the ON state (mean difference = − 2.88; p = 0.01; I<sup>2</sup> = 30%), although they were associated with a higher incidence of adverse events across all safety outcomes. Findings and conclusions of this review will contribute to a clearer understanding of the therapeutic potential of GLP-1 receptor agonists in PD, guiding future clinical research and treatment strategies.</p>
<section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Glucagon-like peptide-1 receptor agonists, Parkinson disease, Motor disorders, Humans, Randomized controlled trials</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Background</h2>
<p id="Par2">Globally, neurological disorders have emerged as a leading cause of disability, particularly with the aging population, contributing to an increase in neurodegenerative diseases. Among these, Parkinson's disease (PD) stands out as the second most prevalent neurodegenerative disorder [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. A meta-analysis conducted in 2016 revealed a staggering 74% increase in the prevalence of PD from 1990 to 2016 [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. This was not attributed only to the increased number of the aging population, since age-standardized prevalence has significantly escalated as well.</p>
<p id="Par3">PD is primarily characterized as a movement disorder, stemming from dopamine depletion in the brain due to the degeneration of dopamine-producing neurons in the substantia nigra (SN), which are crucial for movement coordination. This manifests by resting tremors, stiffness, and imbalance, among others. Various hypotheses have emerged regarding the underlying mechanisms of neuroinflammation and degeneration, including the abnormal clearance of α-synuclein protein in affected neurons, mitochondrial dysfunction, and oxidative stress [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>].</p>
<p id="Par4">Impaired glucose metabolism in PD patients exists in the early stages of the disease [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. This impairment may be attributed to various mechanisms, such as insulin resistance, oxidative stress, and blood–brain barrier dysfunction [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. Impaired insulin signaling can lead to mitochondrial dysfunction that is characterized by compromised energy metabolism, which is detrimental to neuronal health. It’s also believed to increase the aggregation of α-synuclein, which is highly toxic to the neurons [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. Insulin resistance also contributes to increased production of reactive oxygen species, further leading to oxidative stress that damages dopaminergic neurons in the SN.</p>
<p id="Par5">Currently, there are no disease-modifying therapies for PD. However, new studies continue to offer insights into optimal symptomatic management [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. A growing body of evidence is studying the relationship between neurodegenerative diseases such as PD and type 2 diabetes mellitus (T2DM). Cohort studies have shown an increased risk of developing PD in individuals with diabetes [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. These findings align with the aforementioned mechanisms of insulin resistance in promoting the pathologies of PD. Furthermore, studies indicate that diabetics treated with glucagon‐like peptide‐1 (GLP‐1) receptor agonists have a <em>reduced risk</em> of PD compared to those on other anti-diabetic medications, suggesting possible neuroprotective effects [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>, <a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>].</p>
<p id="Par6">GLP-1 receptor agonists are FDA-approved treatments for T2DM and act by triggering insulin release by stimulating the GLP-1 receptor in the pancreas. Their recognized <em>neuroprotection</em> in PD models is thought to arise from their promotion of survival of dopaminergic neurons in the SN. This effect is presented through several mechanisms, such as reducing oxidative stress, apoptosis, and inflammation [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>, <a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. Additionally, these agents have been found to resensitize insulin signaling in the brain, potentially addressing metabolic impairments associated with PD [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>].</p>
<p id="Par7">Clinical trials investigating GLP-1 receptor agonists in PD patients have yielded mixed results regarding their impact on both motor and non-motor symptoms of the disease as well as related adverse events. Given their promising efficacy in addressing PD pathologies, it is vital to evaluate both the magnitude and direction of their effects on clinically significant PD symptoms. Consequently, this systematic review and meta-analysis aims to assess the safety and efficacy of GLP-1 receptor agonists for individuals suffering from PD.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<p id="Par8">We followed the Preferred Reporting Items of Systematic Reviews and Meta-Analysis (<em>PRISMA</em>) statement guidelines to report this review [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. All steps were done in strict accordance with the <em>Cochrane Handbook for Systematic Reviews of Interventions version 6.4</em> [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. This review was registered a priori on the International Prospective Register of Systematic Reviews (PROSPERO) under the <em>ID CRD42024594452</em>.</p>
<section id="Sec3"><h3 class="pmc_sec_title">Criteria for considering studies for this review</h3>
<section id="Sec4"><h4 class="pmc_sec_title">Types of studies</h4>
<p id="Par9">We aimed to gather present evidence that investigates the role of GLP-1 receptor agonists in PD patients. We considered studies that are ongoing or completed, published or unpublished, and trials that are randomized or nonrandomized for inclusion in this review. The inclusion of <em>ongoing studies</em> (summarizing their characteristics and including them in the synthesis of evidence) and unpublished trials is recommended by methodological guidelines and stated by <em>Cochrane Handbook</em> [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. For unpublished trials, we searched trial registries (such as clinicaltrials.gov) and preprint websites and obtained results of an included trial in this review through a combination of both [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>].</p>
<p id="Par10">If a trial is reported in more than one report, we included all reports and extracted data from them all while paying close attention so as not to report duplicated data. These reports could be preprints, journal articles of the main results, and post hoc analyses [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. We did not prioritize a type of published report to be extracted if there was a conflict between reports and resolved these conflicts by discussion to reach the most appropriate data.</p>
<p id="Par11">There was no restriction for publication language, year of dissemination, or setting. As stated by methodological guidelines, reported outcomes in the trials were not used as eligibility criteria [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Cross-over trials were intended to be excluded since the applicability of their results in PD is doubtful; however, our search did not recall any such trials related to the topic [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>].</p></section><section id="Sec5"><h4 class="pmc_sec_title">Participants</h4>
<p id="Par12">We included subjects diagnosed with PD with any validated tool, with no restriction of age, disease stage, or number of participating patients in a trial.</p></section><section id="Sec6"><h4 class="pmc_sec_title">Types of interventions</h4>
<p id="Par13">GLP-1 receptor agonists are the intervention of interest in this review, with no restrictions on dose, route of administration, duration of treatment, or specific drug in this family. Comparators were control groups (groups receiving no treatment or usual care) or placebo groups. Comparators are referred to as “placebo” in the plots.</p></section></section><section id="Sec7"><h3 class="pmc_sec_title">Types of outcome measures</h3>
<section id="Sec8"><h4 class="pmc_sec_title">Primary outcomes</h4>
<p id="Par14">Primary outcomes included PD motor impairment as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) subscale Part III in the on-medication state in endpoints and midpoints of included studies and in the off-medication state in endpoints and midpoints of included studies [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. Other primary outcomes included PD motor complications as measured by MDS-UPDRS Part IV in endpoints of included studies, motor experiences of daily living in PD patients as measured by MDS-UPDRS Part II in endpoints of included studies, gastrointestinal adverse events of GLP-1 receptor agonists, including dyspepsia, vomiting, diarrhea, and constipation, as well as general adverse events such as headache and fatigue.</p></section><section id="Sec9"><h4 class="pmc_sec_title">Secondary outcomes</h4>
<p id="Par15">Secondary outcomes included non-motor symptoms of PD as measured by the Non-Motor Symptoms Scale (NMSS), quality of life of PD patients as measured by the Parkinson’s Disease Questionnaire (PDQ)‐39, and changes in levodopa equivalent doses (LED) from baseline to endpoints.</p>
<p id="Par16">Choosing <em>motor outcomes</em> to be included as critical outcomes in the comparison of GLP-1 receptor agonists vs. control or placebo groups was based on their significance in the lives of individuals with PD in accordance with Hammarlund et al., who stated these are the most important outcomes [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. In addition, adverse events were of such interest in this review to complete the efficacy and safety profiles of GLP-1 receptor agonists in PD treatment. Furthermore, irrespective of the importance of these outcomes, the outcomes of quality of life of subjects with PD, non-motor symptoms, and required daily doses of medications were considered to be of clinical importance for them to maintain a more convenient life with fewer drug side effects.</p></section></section><section id="Sec10"><h3 class="pmc_sec_title">Search methods for identification of studies</h3>
<section id="Sec11"><h4 class="pmc_sec_title">Electronic searches</h4>
<p id="Par17">A comprehensive search of electronic databases, including PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, Web of Science, and Embase, has been performed on 9/9/2024 for articles relating to PD and GLP-1 receptor agonists with keywords that include the following: ((Parkinson) OR (Parkinson*) OR (Parkinson's)) AND ((Glucagon) OR (GLP-1) OR (Glucagon-like peptide-1) OR (Dulaglutide) OR (Exenatide) OR (Liraglutide) OR (Lixisenatide) OR (Semaglutide) OR (Tirzepatide)).</p></section><section id="Sec12"><h4 class="pmc_sec_title">Searching other resources</h4>
<p id="Par18">We searched the internet for more relevant studies to include. This included searching the trials registry at clinicaltrials.gov. Moreover, searching for comments or errata for the included studies was done [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. We hand-searched the included studies for other eligible ones. The hand search includes backward and afterward searches [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. In the backward search, we searched the listed references of included studies, while in the afterward search, we used websites such as Google Scholar and <a href="https://www.uww.edu/library" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.uww.edu/library</a> (the University of Wisconsin–Whitewater’s library website) to identify where each of the included studies was cited.</p></section></section><section id="Sec13"><h3 class="pmc_sec_title">Data collection and analysis</h3>
<section id="Sec14"><h4 class="pmc_sec_title">Selection of studies</h4>
<p id="Par19">Studies retrieved from different databases were merged together, then duplicates were deleted using the reference management software EndNote Web [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Following this, results were uploaded to Rayyan software [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>] to conduct the screening process of the literature search results. Studies were screened in two rounds. The first was a blinded title and abstract screening. In the second phase, a full-text article screening of the potentially eligible abstracts was conducted. Each study was judged by two independent authors, and any disagreements were resolved by consulting a third reviewer. We excluded studies that did not match our model of population and intervention under investigation.</p></section><section id="Sec15"><h4 class="pmc_sec_title">Data extraction and management</h4>
<p id="Par20">We used a customized Google spreadsheet for data extraction that was accessible to all authors. All reviewers took part in the data extraction. Data from each study was extracted independently by two authors. Any disagreements were resolved through discussion between the two reviewers, and sometimes a third reviewer participated. Extracted data were mainly divided into five domains: study characteristics, characteristics of the included studies’ population, risk of bias domains, and results of studies, including results of the efficacy profile and adverse events. Characteristics of the included studies included study ID (last name of the first author and the publication year), study design, country, sample size, intervention, and comparator. Characteristics of the population included the assigned intervention, age (years), sex (male, %), weight (kg), body mass index (BMI, kg/m2), time since diagnosis (years), baseline MDS-UPDRS Part III on-state, MDS-UPDRS Part III off-state, and MDS-UPDRS Part IV, and MDS-UPDRS Part II.</p>
<p id="Par21">Some data in the trials’ reports were represented in graphs, and two reviewers independently used PlotDigitizer [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>] for its extraction. As we were looking forward to comparing the efficacy of GLP-1 receptor agonists in midpoints and endpoints, data from these time points were extracted separately. The midpoint of interest was 6 months after the application of the intervention, and the endpoint of interest was the actual endpoint in the included studies. Table <a href="#Tab1" class="usa-link">1</a> shows the timepoints when data were obtained from patients in the included studies. Continuous data that was not reported as mean and standard deviation (SD) was converted to this format using the Meta-Analysis Accelerator website [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>].
</p>
<section class="tw xbox font-sm" id="Tab1"><h5 class="obj_head">Table 1.</h5>
<div class="caption p"><p>Timepoints of outcome assessments in the included trials [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>–<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Study name</th>
<th align="left" colspan="1" rowspan="1">Intervention</th>
<th align="left" colspan="1" rowspan="1">Timepoint 1</th>
<th align="left" colspan="1" rowspan="1">Timepoint 2</th>
<th align="left" colspan="1" rowspan="1">Timepoint 3</th>
<th align="left" colspan="1" rowspan="1">Timepoint 4</th>
<th align="left" colspan="1" rowspan="1">Timepoint 5</th>
<th align="left" colspan="1" rowspan="1">Timepoint 6</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Athauda 2017</td>
<td align="left" colspan="1" rowspan="1">Exenatide</td>
<td align="left" colspan="1" rowspan="1">12 weeks</td>
<td align="left" colspan="1" rowspan="1">24 weeks*</td>
<td align="left" colspan="1" rowspan="1">36 weeks</td>
<td align="left" colspan="1" rowspan="1">48 weeks</td>
<td align="left" colspan="1" rowspan="1">60 weeks<sup>#</sup>
</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Aviles-Olmos 2013</td>
<td align="left" colspan="1" rowspan="1">Exenatide</td>
<td align="left" colspan="1" rowspan="1">26 weeks*</td>
<td align="left" colspan="1" rowspan="1">48 weeks</td>
<td align="left" colspan="1" rowspan="1">52 weeks<sup>#</sup>
</td>
<td align="left" colspan="1" rowspan="1">56 weeks</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Malatt 2022</td>
<td align="left" colspan="1" rowspan="1">Liraglutide</td>
<td align="left" colspan="1" rowspan="1">28 weeks*</td>
<td align="left" colspan="1" rowspan="1">54 weeks<sup>#</sup>
</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">McGarry 2024</td>
<td align="left" colspan="1" rowspan="1">NLY01 2.5, 5 mg</td>
<td align="left" colspan="1" rowspan="1">4 weeks</td>
<td align="left" colspan="1" rowspan="1">8 weeks</td>
<td align="left" colspan="1" rowspan="1">12 weeks</td>
<td align="left" colspan="1" rowspan="1">24 weeks*</td>
<td align="left" colspan="1" rowspan="1">36 weeks</td>
<td align="left" colspan="1" rowspan="1">44 weeks<sup>#</sup>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Meissner 2024</td>
<td align="left" colspan="1" rowspan="1">Lixisenatide</td>
<td align="left" colspan="1" rowspan="1">26 weeks*</td>
<td align="left" colspan="1" rowspan="1">52 weeks<sup>#</sup>
</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p24">
<p><sup>*</sup>: Timepoints used as midpoints and pooled together</p>
<p><sup>#</sup>: Timepoints used as endpoints and pooled together</p>
</div></div></section></section><section id="Sec16"><h4 class="pmc_sec_title">Assessment of risk of bias in included studies</h4>
<p id="Par22">The quality of the studies included in this review was assessed by two independent reviewers using the Cochrane risk of bias tool 2 (RoB 2) [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. The Cochrane RoB 2 has seven study domains, including random sequence generation, allocation concealment, blinding of the investigators and participants, blinding of the outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias. For each domain, studies were categorized as having a “low risk,” “high risk,” or “some concerns” of bias.</p></section><section id="Sec17"><h4 class="pmc_sec_title">Measures of treatment effect</h4>
<p id="Par23">To calculate the pooled effect estimates of efficacy outcomes of GLP-1 receptor agonists vs. controls, continuous data was analyzed based on mean and SD with the total number of participants in each study group (N) to calculate the mean difference (MD) with 95% confidence interval (CI). Standardized mean difference (SMD) was not used as the studies used the same scale in each outcome domain. In addition, risk ratios (RR) were used to express the pooled effects of GLP-1 receptor agonists vs. placebo regarding adverse events of their application. Dichotomous data was extracted to calculate RRs.</p></section><section id="Sec18"><h4 class="pmc_sec_title">Unit of analysis issues</h4>
<p id="Par24">Our unit of analysis was the PD patient. One included study had three arms: two arms for the drug with different doses and one arm for placebo. In each outcome, we combined the results of the two drug arms [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. We did not choose to extract data of only one arm in order not to arbitrarily omit a relevant group to our research question [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Also, we did not include both arms in one meta-analysis separately in order not to double count the placebo group, which would raise unit-of-analysis issues in our synthesis [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Moreover, combining both arms of the drug is justified best in this case by our research question, which investigates the overall effect of the GLP-1 receptor agonists in PD treatment, not to compare the effect of different doses of one drug in this drug family.</p></section><section id="Sec19"><h4 class="pmc_sec_title">Dealing with missing data</h4>
<p id="Par25">For potentially measured but unreported data that are of our interest in included trials, we emailed the authors of these trials to ask for it. Additionally, one included study in this review (<em>Malatt 2022</em>) does not have a full-text journal article. However, the registry of the trial on ClinicalTrials.gov had the baseline characteristics of participants and detailed results, and it has a preprint with full data [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. Moreover, this trial is reported in an abstract in <em>Neurology journal</em> [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. We collated data from all these sources [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>].</p></section><section id="Sec20"><h4 class="pmc_sec_title">Synthesis methods</h4>
<p id="Par26">We conducted a meta-analysis to demonstrate the pooled effect estimates using Review Manager (RevMan) version 5.4.1 [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. We intended to use a random-effect meta-analysis model in efficacy outcomes comparisons since the interventions in studies are not the same drug, which explains heterogeneity if it is noted. We, however, used a fixed-effect model in the adverse events meta-analyses since adverse events of GLP-1 receptor agonists are profoundly similar. Pooled effect measures for continuous outcomes were intended to be reported using the inverse variance method, and for dichotomous outcomes, the Mantel–Haenszel methods.</p></section><section id="Sec21"><h4 class="pmc_sec_title">Subgroup analysis</h4>
<p id="Par27">We aimed to conduct a subgroup analysis based on the time since diagnosis with PD (early and late subgroups) when sufficient data exists.</p></section><section id="Sec22"><h4 class="pmc_sec_title">Sensitivity analysis</h4>
<p id="Par28">In the MDS-UPDRS Part III outcome domain, sensitivity analysis was intended to assess the robustness of the evidence. This was done multiple times, excluding a different study in each instance.</p></section></section></section><section id="Sec23"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec24"><h3 class="pmc_sec_title">Description of studies</h3>
<section id="Sec25"><h4 class="pmc_sec_title">Results of the search</h4>
<p id="Par29">The search of PubMed, Scopus, CENTRAL, Web of Science, and Embase yielded 2084 entries. After removing duplicates and screening the titles and abstracts of 1426 records, 46 studies were identified as potentially relevant and underwent full-text review. Of these, only five trials met the inclusion criteria and were included in the final analysis [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>, <a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. We also identified five ongoing studies on the review topic. Figure <a href="#Fig1" class="usa-link">1</a> presents the PRISMA flowchart, detailing the study selection process and reasons for the exclusion of studies during the full-text screening phase.</p>
<figure class="fig xbox font-sm" id="Fig1"><h5 class="obj_head">Fig. 1.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/69da527712cb/13098_2025_1888_Fig1_HTML.jpg" loading="lazy" id="MO1" height="835" width="710" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>PRISMA flow diagram of the review</p></figcaption></figure></section><section id="Sec26"><h4 class="pmc_sec_title">Included studies</h4>
<p id="Par30">Five studies reported in 16 reports were included in the synthesis. Athauda 2017 was reported in five reports, including 3 reports of post-hoc analyses [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>–<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. In addition, Aviles-Olmos 2013 has 6 records [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>, <a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>–<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. Malatt 2022 is described in three reports [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>, <a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. The included clinical trials in the quantitative synthesis were published between 2013 and 2024, involving a total of 580 patients with PD. These studies were conducted in various countries, including the United States, the United Kingdom, and France. All studies were double-blind randomized controlled trials (RCTs), except for the study by Aviles-Olmos [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>], which was a single-blind RCT. In these trials, participants were randomized to receive a GLP-1 receptor agonist intervention at various doses and placebo plus usual care or standard care only as control groups. The GLP-1 receptor agonists used in these trials included exenatide, liraglutide, NLY01 (a pegylated analogue of exenatide), and lixisenatide.</p>
<p id="Par31">A summary of the included study characteristics is presented in Table <a href="#Tab2" class="usa-link">2</a>, while the baseline characteristics of the participants are shown in Table <a href="#Tab3" class="usa-link">3</a>.
</p>
<section class="tw xbox font-sm" id="Tab2"><h5 class="obj_head">Table 2.</h5>
<div class="caption p"><p>Summary of the included studies</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Study ID</th>
<th align="left" colspan="1" rowspan="1">Study design</th>
<th align="left" colspan="1" rowspan="1">Registration (NCT)</th>
<th align="left" colspan="1" rowspan="1">Follow‐up duration (w)</th>
<th align="left" colspan="1" rowspan="1">Country</th>
<th align="left" colspan="1" rowspan="1">N randomized</th>
<th align="left" colspan="1" rowspan="1">Type of Analysis</th>
<th align="left" colspan="1" rowspan="1">Diagnostic criteria</th>
<th align="left" colspan="1" rowspan="1">Intervention (s)</th>
<th align="left" colspan="1" rowspan="1">Comparator</th>
<th align="left" colspan="1" rowspan="1">Outcomes assessed</th>
<th align="left" colspan="1" rowspan="1">Findings</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Athauda 2017 [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]</td>
<td align="left" colspan="1" rowspan="1">Double-blind RCT</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01971242" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01971242</a></td>
<td align="left" colspan="1" rowspan="1">60</td>
<td align="left" colspan="1" rowspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">62</td>
<td align="left" colspan="1" rowspan="1">ITT</td>
<td align="left" colspan="1" rowspan="1">Queen Square Brain Bank criteria</td>
<td align="left" colspan="1" rowspan="1">S.c. exenatide 2 mg once weekly + usual care</td>
<td align="left" colspan="1" rowspan="1">Placebo</td>
<td align="left" colspan="1" rowspan="1">MDS-UPDRS part III, NMSS, PDQ-39, LED, MADRS, MDRS, and Unified Dyskinesia Rating Scale</td>
<td align="left" colspan="1" rowspan="1">Exenatide had positive, sustained effects on motor and non-motor scores in PD patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Aviles-Olmos 2013 [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]</td>
<td align="left" colspan="1" rowspan="1">Single-blind RCT</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01174810" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01174810</a></td>
<td align="left" colspan="1" rowspan="1">52</td>
<td align="left" colspan="1" rowspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">44</td>
<td align="left" colspan="1" rowspan="1">PP</td>
<td align="left" colspan="1" rowspan="1">Queen Square Brain Bank criteria</td>
<td align="left" colspan="1" rowspan="1">S.c. exenatide 5 μg or 10 μg BID + usual care</td>
<td align="left" colspan="1" rowspan="1">Usual care</td>
<td align="left" colspan="1" rowspan="1">MDS-UPDRS part III, part IV, part II, part I, PDQ-39, LED, MADRS, MDRS, Dyskinesia Rating Scale, and safety</td>
<td align="left" colspan="1" rowspan="1">Exenatide had clinically relevant improvements in PD across motor and cognitive measures</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Malatt 2022 [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]</td>
<td align="left" colspan="1" rowspan="1">Double-blind RCT</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT02953665" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02953665</a></td>
<td align="left" colspan="1" rowspan="1">54</td>
<td align="left" colspan="1" rowspan="1">US</td>
<td align="left" colspan="1" rowspan="1">63</td>
<td align="left" colspan="1" rowspan="1">PP</td>
<td align="left" colspan="1" rowspan="1">UK Brain Bank Criteria</td>
<td align="left" colspan="1" rowspan="1">S.c. Liraglutide 0.6–1.8 mg daily + usual care</td>
<td align="left" colspan="1" rowspan="1">Placebo + usual care</td>
<td align="left" colspan="1" rowspan="1">MDS-UPDRS part III, part IV, part II, part I, NMSS, PDQ-39, LED, MDRS, and safety</td>
<td align="left" colspan="1" rowspan="1">Liraglutide showed no significant effect on motor symptoms but improved non-motor symptoms, unlike placebo, which worsened them</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">McGarry 2024 [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]</td>
<td align="left" colspan="1" rowspan="1">Double-blind RCT</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04154072" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04154072</a></td>
<td align="left" colspan="1" rowspan="1">44</td>
<td align="left" colspan="1" rowspan="1">US</td>
<td align="left" colspan="1" rowspan="1">255</td>
<td align="left" colspan="1" rowspan="1">ITT</td>
<td align="left" colspan="1" rowspan="1">UK Brain Bank Criteria</td>
<td align="left" colspan="1" rowspan="1">S.c. NLY01 2.5 mg, NLY01 5 mg once weekly</td>
<td align="left" colspan="1" rowspan="1">Placebo</td>
<td align="left" colspan="1" rowspan="1">MDS-UPDRS part III, part II, and part I, NMSS, PDQ-39, SE-ADL, MoCA, SCOPA-Cog, and safety</td>
<td align="left" colspan="1" rowspan="1">NLY01 at 2.5 and 5 mg was not associated with any improvement in PD motor or non-motor features compared with placebo</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Meissner 2024 [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]</td>
<td align="left" colspan="1" rowspan="1">Double-blind RCT</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03439943" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03439943</a></td>
<td align="left" colspan="1" rowspan="1">52</td>
<td align="left" colspan="1" rowspan="1">France</td>
<td align="left" colspan="1" rowspan="1">156</td>
<td align="left" colspan="1" rowspan="1">ITT</td>
<td align="left" colspan="1" rowspan="1">UK Brain Bank Criteria</td>
<td align="left" colspan="1" rowspan="1">S.c. lixisenatide 10 μg or 20 μg daily + usual care</td>
<td align="left" colspan="1" rowspan="1">Placebo + usual care</td>
<td align="left" colspan="1" rowspan="1">MDS-UPDRS part III, part IV, part II, part I, LED, and safety</td>
<td align="left" colspan="1" rowspan="1">Lixisenatide therapy resulted in less progression of motor disability than placebo but was associated with gastrointestinal side effects</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p38"><p><em>ITT</em> Intention to treat, <em>PP</em> Per protocol, <em>RCT</em> randomized clinical trial, <em>S.c.</em> subcutaneous, <em>N</em> Sample size, <em>MDR-UPDRS</em> Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease, <em>MMSE</em> Mini-Mental State Examination, <em>MoCA</em> Montreal Cognitive Assessment, <em>PDQ-39</em> Parkinson’s Disease Questionnaire</p></div></div></section><section class="tw xbox font-sm" id="Tab3"><h5 class="obj_head">Table 3.</h5>
<div class="caption p"><p>Baseline characteristics of the included studies’ populations</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Study ID</th>
<th align="left" colspan="1" rowspan="1">Interventions</th>
<th align="left" colspan="1" rowspan="1">Age in years (SD)</th>
<th align="left" colspan="1" rowspan="1">Male N (%)</th>
<th align="left" colspan="1" rowspan="1">Weight in kg (SD)</th>
<th align="left" colspan="1" rowspan="1">BMI in kg/m<sup>2</sup> (SD)</th>
<th align="left" colspan="1" rowspan="1">Time since diagnosis (year)</th>
<th align="left" colspan="1" rowspan="1">Age at PD onset in years (SD)</th>
<th align="left" colspan="1" rowspan="1">LED</th>
<th align="left" colspan="1" rowspan="1">MDS-UPDRS part III on state</th>
<th align="left" colspan="1" rowspan="1">MDS-UPDRS part III off state</th>
<th align="left" colspan="1" rowspan="1">MDS-UPDRS part II</th>
<th align="left" colspan="1" rowspan="1">MDS-UPDRS part IV</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="2" colspan="1">Athauda 2017 [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]</td>
<td align="left" colspan="1" rowspan="1">Exenatide</td>
<td align="left" colspan="1" rowspan="1">61.6 (8.2)</td>
<td align="left" colspan="1" rowspan="1">22 (71%)</td>
<td align="left" colspan="1" rowspan="1">81.8 (16.6)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">6·4 (3.3)</td>
<td align="left" colspan="1" rowspan="1">55.9 (7.9)</td>
<td align="left" colspan="1" rowspan="1">773.9 (260.9)</td>
<td align="left" colspan="1" rowspan="1">19.4 (8.4)</td>
<td align="left" colspan="1" rowspan="1">32.8 (9.7)</td>
<td align="left" colspan="1" rowspan="1">12.5 (6.7)</td>
<td align="left" colspan="1" rowspan="1">4.7 (3.1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Placebo</td>
<td align="left" colspan="1" rowspan="1">57.8 (8.0)</td>
<td align="left" colspan="1" rowspan="1">22 (76%)</td>
<td align="left" colspan="1" rowspan="1">80.8 (12.9)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">6·4 (3.3)</td>
<td align="left" colspan="1" rowspan="1">52.2 (7.7)</td>
<td align="left" colspan="1" rowspan="1">825.7 (215)</td>
<td align="left" colspan="1" rowspan="1">14.4 (8.2)</td>
<td align="left" colspan="1" rowspan="1">27.1 (10.3)</td>
<td align="left" colspan="1" rowspan="1">10.7 (5.3)</td>
<td align="left" colspan="1" rowspan="1">5.3 (3.0)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Aviles-Olmos 2013 [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]</td>
<td align="left" colspan="1" rowspan="1">Exenatide</td>
<td align="left" colspan="1" rowspan="1">61.4 (6.0)</td>
<td align="left" colspan="1" rowspan="1">15 (75%)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">9.6 (3.4)</td>
<td align="left" colspan="1" rowspan="1">51.6 (7.8)</td>
<td align="left" colspan="1" rowspan="1">973 (454)</td>
<td align="left" colspan="1" rowspan="1">23.5 (6.3)</td>
<td align="left" colspan="1" rowspan="1">31.0 (11.2)</td>
<td align="left" colspan="1" rowspan="1">10.2 (5.2)</td>
<td align="left" colspan="1" rowspan="1">6.3 (2.4)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Usual care</td>
<td align="left" colspan="1" rowspan="1">59.4 (8.4)</td>
<td align="left" colspan="1" rowspan="1">20 (83%)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">11.0 (5.9)</td>
<td align="left" colspan="1" rowspan="1">48.4 (7.4)</td>
<td align="left" colspan="1" rowspan="1">977 (493)</td>
<td align="left" colspan="1" rowspan="1">25.3 (10.7)</td>
<td align="left" colspan="1" rowspan="1">34.0 (16.1)</td>
<td align="left" colspan="1" rowspan="1">12.9 (6.2)</td>
<td align="left" colspan="1" rowspan="1">6.3 (3.4)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Malatt 2022 [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]</td>
<td align="left" colspan="1" rowspan="1">Liraglutide</td>
<td align="left" colspan="1" rowspan="1">63.5 (9.8)</td>
<td align="left" colspan="1" rowspan="1">25 (67.6%)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">28 (5.2)</td>
<td align="left" colspan="1" rowspan="1">4.7 (3.1)</td>
<td align="left" colspan="1" rowspan="1">58.9 (10.5)</td>
<td align="left" colspan="1" rowspan="1">564 (327)</td>
<td align="left" colspan="1" rowspan="1">14.8 (7.1)</td>
<td align="left" colspan="1" rowspan="1">26.1 (9.6)</td>
<td align="left" colspan="1" rowspan="1">8.8 (5.4)</td>
<td align="left" colspan="1" rowspan="1">3.8 (3.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Placebo</td>
<td align="left" colspan="1" rowspan="1">64.2 (6.4)</td>
<td align="left" colspan="1" rowspan="1">13 (72.2%)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">27.9 (4.6)</td>
<td align="left" colspan="1" rowspan="1">4.8 (3.3)</td>
<td align="left" colspan="1" rowspan="1">59.3 (7.5)</td>
<td align="left" colspan="1" rowspan="1">640 (360)</td>
<td align="left" colspan="1" rowspan="1">16.3 (9.2)</td>
<td align="left" colspan="1" rowspan="1">28.8 (10.7)</td>
<td align="left" colspan="1" rowspan="1">7.6 (5.0)</td>
<td align="left" colspan="1" rowspan="1">3.6 (3.2)</td>
</tr>
<tr>
<td align="left" rowspan="3" colspan="1">McGarry 2024 [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]</td>
<td align="left" colspan="1" rowspan="1">NLY01 2.5 mg</td>
<td align="left" colspan="1" rowspan="1">62.1 (9.0)</td>
<td align="left" colspan="1" rowspan="1">60 (71%)</td>
<td align="left" colspan="1" rowspan="1">80.8 (16.6)</td>
<td align="left" colspan="1" rowspan="1">26.42 (4.14)</td>
<td align="left" colspan="1" rowspan="1">1.02 (1.04)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">22.7 (8.1)</td>
<td align="left" colspan="1" rowspan="1">4.8 (3.6)</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NLY01 5 mg</td>
<td align="left" colspan="1" rowspan="1">60.6 (10.0)</td>
<td align="left" colspan="1" rowspan="1">54 (64%)</td>
<td align="left" colspan="1" rowspan="1">79.1 (17.4)</td>
<td align="left" colspan="1" rowspan="1">25.81 (4.58)</td>
<td align="left" colspan="1" rowspan="1">0.96 (0.94)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">22.0 (8.2)</td>
<td align="left" colspan="1" rowspan="1">5.0· (4.1)</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Placebo</td>
<td align="left" colspan="1" rowspan="1">61.8 (8.1)</td>
<td align="left" colspan="1" rowspan="1">52 (62%)</td>
<td align="left" colspan="1" rowspan="1">77.8 (16.2)</td>
<td align="left" colspan="1" rowspan="1">26.03 (4.66)</td>
<td align="left" colspan="1" rowspan="1">0.9 (0.996)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">22·3 (9.1)</td>
<td align="left" colspan="1" rowspan="1">4.9 (3.6)</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Meissner 2024 [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]</td>
<td align="left" colspan="1" rowspan="1">Lixisenatide</td>
<td align="left" colspan="1" rowspan="1">59.5 (8.1)</td>
<td align="left" colspan="1" rowspan="1">44 (56)</td>
<td align="left" colspan="1" rowspan="1">75 (15.8)</td>
<td align="left" colspan="1" rowspan="1">25.6 (3.9)</td>
<td align="left" colspan="1" rowspan="1">1.4 (0.8)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">317 (179)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">14.8 (7.3)</td>
<td align="left" colspan="1" rowspan="1">5.0 (3.5)</td>
<td align="left" colspan="1" rowspan="1">0.3 (1.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><strong>Placebo</strong></td>
<td align="left" colspan="1" rowspan="1">59.9 (8.4)</td>
<td align="left" colspan="1" rowspan="1">48 (62)</td>
<td align="left" colspan="1" rowspan="1">76.7 (15.7)</td>
<td align="left" colspan="1" rowspan="1">25.8 (4.2)</td>
<td align="left" colspan="1" rowspan="1">1.4 (0.7)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">355 (215)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">15.5 (7.8)</td>
<td align="left" colspan="1" rowspan="1">5.4 (4.3)</td>
<td align="left" colspan="1" rowspan="1">0.2 (0.8)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p40">
<p>All qualitative variables are represented as number (percentage), while quantitative variables are shown in Mean (Standard deviation)</p>
<p><em>LED</em> levodopa equivalent dose, <em>MDR-UPDRS</em> Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease, <em>SD</em> Standard deviation</p>
</div></div></section></section><section id="Sec27"><h4 class="pmc_sec_title">Ongoing studies</h4>
<p id="Par32">Our search has detected five ongoing trials that aim to assess the effects of GLP-1 receptor agonists in individuals with PD. Exenatide has predominated the intervention groups across trials, which is justified by the favorable results from the completed trials (see Table <a href="#Tab2" class="usa-link">2</a>). A summary of their status, interventions, follow-up durations, and main outcomes is shown in Table <a href="#Tab4" class="usa-link">4</a>. These ongoing trials vary in their methodologies, outcomes of interest, and even in how outcomes are assessed. Once completed and published, they will yield reasonable evidence about the true evaluation of GLP-1 receptor agonists in PD.
</p>
<section class="tw xbox font-sm" id="Tab4"><h5 class="obj_head">Table 4.</h5>
<div class="caption p"><p>Summary of ongoing studies</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">PI</th>
<th align="left" colspan="1" rowspan="1">NCT</th>
<th align="left" colspan="1" rowspan="1">Status<sup>a</sup>
</th>
<th align="left" colspan="1" rowspan="1">N<sup>b</sup>
</th>
<th align="left" colspan="1" rowspan="1">Medication</th>
<th align="left" colspan="1" rowspan="1">Follow up</th>
<th align="left" colspan="1" rowspan="1">Main outcomes</th>
<th align="left" colspan="1" rowspan="1">Results</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Vaillancourt [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03456687" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03456687</a></td>
<td align="left" colspan="1" rowspan="1">Completed</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Exenatide</td>
<td align="left" colspan="1" rowspan="1">1 year</td>
<td align="left" colspan="1" rowspan="1">
<p>Change in free-water accumulation in the substantia nigra</p>
<p>Change in BOL signal in the posterior putamen</p>
<p>Change in BOL signal in M1</p>
<p>Change in BOL signal in the SMA</p>
</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Foltynie [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04232969" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04232969</a></td>
<td align="left" colspan="1" rowspan="1">Active, not recruiting</td>
<td align="left" colspan="1" rowspan="1">194</td>
<td align="left" colspan="1" rowspan="1">Exenatide</td>
<td align="left" colspan="1" rowspan="1">2 years</td>
<td align="left" colspan="1" rowspan="1">
<p>MDS-UPDRS Part III (ON state)</p>
<p>MDS-UPDRS Part IV and II (OFF state)</p>
<p>PHQ-9</p>
<p>PDQ-39</p>
<p>NMSS</p>
</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Min Ho Ihm [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04269642" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04269642</a></td>
<td align="left" colspan="1" rowspan="1">Unknown</td>
<td align="left" colspan="1" rowspan="1">99</td>
<td align="left" colspan="1" rowspan="1">Exenatide SR</td>
<td align="left" colspan="1" rowspan="1">60 weeks</td>
<td align="left" colspan="1" rowspan="1">
<p>MDS-UPDRS Part III</p>
<p>Specific to non-specific binding ratio (confirmed by PET scan)</p>
<p>MDS-UPDRS Part I, II, and IV</p>
<p>PDQ-39</p>
<p>MoCA</p>
<p>NMSS</p>
</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NA [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03659682" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03659682</a></td>
<td align="left" colspan="1" rowspan="1">Not yet recruiting</td>
<td align="left" colspan="1" rowspan="1">120</td>
<td align="left" colspan="1" rowspan="1">Semaglutide</td>
<td align="left" colspan="1" rowspan="1">48 months</td>
<td align="left" colspan="1" rowspan="1">
<p>MDS-UPDRS Part III (OFF state)</p>
<p>Levodopa equivalents</p>
<p>Nigrostriatal degeneration (assessed by changes in DAT-scan uptake)</p>
<p>Cognitive function</p>
</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Svenningsson [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]</td>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04305002" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04305002</a></td>
<td align="left" colspan="1" rowspan="1">Unknown</td>
<td align="left" colspan="1" rowspan="1">60</td>
<td align="left" colspan="1" rowspan="1">Exenatide</td>
<td align="left" colspan="1" rowspan="1">21 months</td>
<td align="left" colspan="1" rowspan="1">
<p>MDS-UPDRS Part III (ON and OFF states)</p>
<p>MDS-UPDRS II and IV</p>
<p>Accelerometer (intensity of physical activity)</p>
<p>Accelerometer (steps per day)</p>
</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p67">
<p><em>BOL</em> Blood Oxygen Level-dependent, <em>MDR-UPDRS</em> Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease, <em>MMSE</em> Mini-Mental State Examination, <em>MoCA</em> Montreal Cognitive Assessment, <em>NA</em> not available, <em>NMSS</em> National Multiple Sclerosis Society, <em>PHQ-9</em> Patient Health Questionnaire, <em>PDQ-39</em> Parkinson’s Disease Questionnaire, <em>PI</em> principal investigator, <em>SR</em> sustained release, <em>SMA</em> Supplementary Motor Area</p>
<p><sup>a</sup> The recruitment status as found in the registration protocol of the trials</p>
<p><sup>b</sup> The actual enrollment (not the estimated enrollment) as found in the registration protocol of the trials</p>
</div></div></section></section></section><section id="Sec28"><h3 class="pmc_sec_title">Risk of bias in included studies</h3>
<p id="Par33">We used the RoB 2 tool to assess the risk of bias for each of the included studies. A summary of the risk of bias assessment is shown in Fig. <a href="#Fig2" class="usa-link">2</a>. No significant risks of bias were observed regarding selection bias, including random sequence generation and missing data. A majority of the studies (4 out of 5) were considered to have a low overall risk of bias, while one report was assessed as having a high overall risk of bias. Except for Aviles-Olmos [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>], which was single-blind, all studies were double-blind in terms of both evaluation and patient treatment. Aviles-Olmos [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>] demonstrated a high risk of bias in two domains, including deviations from the intended intervention, and key clinical outcomes in PD patients were not initially measured for the study participants. In addition, Meissner 2024 has a limited management of key clinical outcomes [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>].</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/917f9624af72/13098_2025_1888_Fig2_HTML.jpg" loading="lazy" id="MO2" height="377" width="778" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Risk of bias summary: The Authors' judgments about each risk of bias item in each included study</p></figcaption></figure></section><section id="Sec29"><h3 class="pmc_sec_title">Primary outcomes results</h3>
<section id="Sec30"><h4 class="pmc_sec_title">MDS-UPDRS subscale Part III ON medication in endpoints</h4>
<p id="Par34">Analysis of endpoint data on MDS-UPDRS Part III in the on-medication state showed a significant improvement in patients treated with GLP-1 receptor agonists compared to those given a placebo (MD = − 2.88; 95% CI − 5.07 to − 0.69; p = 0.01), with insignificant heterogeneity detected (I<sup>2</sup> = 30%, p = 0.23) (Fig. <a href="#Fig3" class="usa-link">3</a>).</p>
<figure class="fig xbox font-sm" id="Fig3"><h5 class="obj_head">Fig. 3.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/4dd6079b2f9f/13098_2025_1888_Fig3_HTML.jpg" loading="lazy" id="MO3" height="149" width="784" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.1: GLP-1 Receptor Agonists vs. placebo in the outcome MDS-UPDRS Part III (on medication) in endpoints</p></figcaption></figure><p id="Par35">Data on the on-medication state for MDS-UPDRS Part III were available from four studies. However, the study by McGarry et al. did not specify whether the MDS-UPDRS Part III assessments were conducted in the on-medication or off-medication state, and the authors did not respond to our inquiries for clarification [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>].</p>
<p id="Par36">To evaluate the robustness of the evidence, we conducted a sensitivity analysis by excluding one study at a time from the meta-analysis to observe changes in the overall pooled results. A significant difference was detected only by excluding <em>Meissner 2024</em> [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. After removing it from the meta-analysis, the effect size for the MDS-UPDRS Part III (on medication) in endpoints shifted to non-significance, indicating that this study may have had a disproportionate influence on the overall findings (MD = − 2.65; 95% CI − 6.44 to 1.15; p = 0.17) (Fig. <a href="#Fig4" class="usa-link">4</a>).</p>
<figure class="fig xbox font-sm" id="Fig4"><h5 class="obj_head">Fig. 4.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/5297cb65c3c1/13098_2025_1888_Fig4_HTML.jpg" loading="lazy" id="MO4" height="149" width="784" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.1.1: GLP-1 receptor agonists vs. placebo, sensitivity analysis by excluding Meissner 2024</p></figcaption></figure></section><section id="Sec31"><h4 class="pmc_sec_title">MDS-UPDRS subscale Part III ON medication in midpoints</h4>
<p id="Par37">An insignificant improvement in the MDS-UPDRS Part III in the on-medication state was detected when pooling effects of GLP-1 receptor agonists vs. placebo in midpoints assessment (MD = − 1.10; 95% CI − 2.74 to 0.53; p = 0.19) with no heterogeneity detected among studies (I<sup>2</sup> = 0%, p = 0.72) (Fig. <a href="#Fig5" class="usa-link">5</a>).</p>
<figure class="fig xbox font-sm" id="Fig5"><h5 class="obj_head">Fig. 5.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/d4ad45a005c5/13098_2025_1888_Fig5_HTML.jpg" loading="lazy" id="MO5" height="147" width="784" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.2: GLP-1 receptor agonists vs. placebo in the outcome MDS-UPDRS Part III (on medication) in midpoints</p></figcaption></figure></section><section id="Sec32"><h4 class="pmc_sec_title">MDS-UPDRS subscale Part III OFF medication in endpoints</h4>
<p id="Par38">Other insignificant improvements were also seen in the MDS-UPDRS Part III in the off-medication state total and subtotal analyses (Fig. <a href="#Fig6" class="usa-link">6</a>). With enough trials for subgrouping in this outcome domain, we conducted a subgroup analysis based on the stage of PD as stated in the trials. Meissner 2024 limited the inclusion for subjects with onset of PD less than 3 years, while McGarry 2024 excluded PD subjects with more than 5 years of diagnosis [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. Therefore, these two studies are included in the “Early PD” subgroup. On the other hand, Aviles-Olmos 2013 only included patients who had PD for more than 5 years [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. Moreover, the remaining two studies [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>] did not specify a duration of the disease for inclusion, and the time since diagnosis in these studies was much higher than in McGarry [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>] and Meissner [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>], as shown in Table <a href="#Tab3" class="usa-link">3</a> [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>].</p>
<figure class="fig xbox font-sm" id="Fig6"><h5 class="obj_head">Fig. 6.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/487785d46365/13098_2025_1888_Fig6_HTML.jpg" loading="lazy" id="MO6" height="297" width="784" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.3: GLP-1 receptor agonists vs placebo, in the outcome MDS-UPDRS Part III (off medication) in endpoints</p></figcaption></figure><p id="Par39">Neither the total (sample size: 331 in the GLP-1 receptor agonists group and 230 in the placebo group) nor the subtotal (sample size: 247 and 159 in early PD and 84 and 71 in late PD, in the GLP-1 receptor agonists group and placebo group, respectively) improvements related to GLP-1 receptor agonists were significant (MD = − 1.32; 95% CI − 3.91 to 1.26; p = 0.32 for total comparison) (MD = − 1.11; 95% CI − 4.49 to 2.27; p = 0.52 for early PD subgroup) (MD = − 1.62; 95% CI − 6.70 to 3.45; p = 0.53 for late PD subgroup).</p></section><section id="Sec33"><h4 class="pmc_sec_title">MDS-UPDRS subscale Part III OFF medication in midpoints</h4>
<p id="Par40">The MDS-UPDRS Part III scores in the off-medication state in midpoints were not reported in Meissner 2024, and we contacted the authors with no response. Our analysis (Fig. <a href="#Fig7" class="usa-link">7</a>) did not show a significant difference between the groups (MD = − 1.60; 95% CI − 4.63 to 1.44; p = 0.30), and no significant heterogeneity was observed (I<sup>2</sup> = 41%, p = 0.16).</p>
<figure class="fig xbox font-sm" id="Fig7"><h5 class="obj_head">Fig. 7.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/6e3d7caff98d/13098_2025_1888_Fig7_HTML.jpg" loading="lazy" id="MO7" height="146" width="784" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.4: GLP-1 receptor agonists vs. placebo in the outcome MDS-UPDRS Part III (off medication) in midpoints</p></figcaption></figure></section><section id="Sec34"><h4 class="pmc_sec_title">MDS-UPDRS Part IV in endpoints</h4>
<p id="Par41">The meta-analysis revealed no significant difference in MDS-UPDRS Part IV for individuals treated with GLP-1 receptor agonists compared to those receiving placebo (MD = − 0.30; 95% CI − 1.02 to 0.41; p = 0.41) (Fig. <a href="#Fig8" class="usa-link">8</a>).</p>
<figure class="fig xbox font-sm" id="Fig8"><h5 class="obj_head">Fig. 8.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig8_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/ca88de331bda/13098_2025_1888_Fig8_HTML.jpg" loading="lazy" id="MO8" height="157" width="782" alt="Fig. 8"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.5: GLP-1 receptor agonists vs. placebo in the outcome MDS-UPDRS Part IV in endpoints</p></figcaption></figure></section><section id="Sec35"><h4 class="pmc_sec_title">MDS-UPDRS Part II in endpoints</h4>
<p id="Par42">As demonstrated in Fig. <a href="#Fig9" class="usa-link">9</a>, an insignificant difference (MD = − 1.85; 95% CI − 3.72 to 0.02; p = 0.05) between the treatment and placebo groups was observed in MDS-UPDRS Part II, with high inter-study heterogeneity (I<sup>2</sup> = 83%, p = 0.0001).</p>
<figure class="fig xbox font-sm" id="Fig9"><h5 class="obj_head">Fig. 9.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig9_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/3c08b2136852/13098_2025_1888_Fig9_HTML.jpg" loading="lazy" id="MO9" height="162" width="784" alt="Fig. 9"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig9/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.6: GLP-1 receptor agonists vs. placebo, in the outcome MDS-UPDRS Part II in endpoints</p></figcaption></figure></section><section id="Sec36"><h4 class="pmc_sec_title">Dyspepsia</h4>
<p id="Par43">Dyspepsia was reported in three studies [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>–<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>], with a total sample of 473 participants (290 receiving GLP-1 receptor agonists and 183 receiving a placebo). The pooled estimate favored the placebo significantly (RR = 3.06; 95% CI 1.39 to 6.74; p = 0.006). There was no heterogeneity (I<sup>2</sup> = 0%, p = 0.50), and a fixed-effect model was applied (Fig. <a href="#Fig10" class="usa-link">10</a>).</p>
<figure class="fig xbox font-sm" id="Fig10"><h5 class="obj_head">Fig. 10.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig10_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/e87dc5bbb4fe/13098_2025_1888_Fig10_HTML.jpg" loading="lazy" id="MO10" height="141" width="784" alt="Fig. 10"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig10/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.7: GLP-1 receptor agonists vs. placebo, in the safety outcome: dyspepsia</p></figcaption></figure></section><section id="Sec37"><h4 class="pmc_sec_title">Vomiting</h4>
<p id="Par44">Data on vomiting were also available from three studies [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>, <a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>], representing 323 participants (151 receiving GLP-1 receptor agonists and 128 receiving a placebo). According to our analysis (Fig. <a href="#Fig11" class="usa-link">11</a>), significant differences favoring the placebo were found (RR = 5.08; 95% CI 1.51 to 17.07; p = 0.009).</p>
<figure class="fig xbox font-sm" id="Fig11"><h5 class="obj_head">Fig. 11.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig11_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/f496ad5dfd0c/13098_2025_1888_Fig11_HTML.jpg" loading="lazy" id="MO11" height="139" width="784" alt="Fig. 11"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig11/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.8: GLP-1 receptor agonists vs. placebo, in the safety outcome: vomiting</p></figcaption></figure></section><section id="Sec38"><h4 class="pmc_sec_title">Diarrhea</h4>
<p id="Par45">In consistency with the previous safety outcomes, diarrhea was more frequent in the GLP-1 receptor agonists group (Fig. <a href="#Fig12" class="usa-link">12</a>).</p>
<figure class="fig xbox font-sm" id="Fig12"><h5 class="obj_head">Fig. 12.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig12_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/0f6875149c84/13098_2025_1888_Fig12_HTML.jpg" loading="lazy" id="MO12" height="153" width="784" alt="Fig. 12"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig12/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.9: GLP-1 receptor agonists vs. placebo, in the safety outcome: diarrhea</p></figcaption></figure></section><section id="Sec39"><h4 class="pmc_sec_title">Constipation</h4>
<p id="Par46">The pooled effect estimate shows a significant difference between the groups, favoring the placebo with an RR of 1.57 and a p-value of 0.01 (Fig. <a href="#Fig13" class="usa-link">13</a>).</p>
<figure class="fig xbox font-sm" id="Fig13"><h5 class="obj_head">Fig. 13.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig13_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/4f0ebbd69218/13098_2025_1888_Fig13_HTML.jpg" loading="lazy" id="MO13" height="153" width="784" alt="Fig. 13"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig13/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.10: GLP-1 receptor agonists vs. placebo, in the safety outcome: constipation</p></figcaption></figure></section><section id="Sec40"><h4 class="pmc_sec_title">Headache</h4>
<p id="Par47">Similarly to diarrhea, headache has an insignificantly higher incidence in the intervention group (RR = 1.19; 95% CI 0.74 to 1.93; p = 0.47) (Fig. <a href="#Fig14" class="usa-link">14</a>).</p>
<figure class="fig xbox font-sm" id="Fig14"><h5 class="obj_head">Fig. 14.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig14_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/9be0a67e1d51/13098_2025_1888_Fig14_HTML.jpg" loading="lazy" id="MO14" height="139" width="784" alt="Fig. 14"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig14/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.11: GLP-1 receptor agonists vs. placebo in the safety outcome: headache</p></figcaption></figure></section><section id="Sec41"><h4 class="pmc_sec_title">Fatigue</h4>
<p id="Par48">The pooled analysis indicated no significant difference between the treatment and placebo groups in fatigue; however, it favored the placebo (Fig. <a href="#Fig15" class="usa-link">15</a>).</p>
<figure class="fig xbox font-sm" id="Fig15"><h5 class="obj_head">Fig. 15.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig15_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/4b23a8e4170a/13098_2025_1888_Fig15_HTML.jpg" loading="lazy" id="MO15" height="140" width="784" alt="Fig. 15"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig15/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 1.12: GLP-1 receptor agonists vs. placebo in the safety outcome: fatigue</p></figcaption></figure></section></section><section id="Sec42"><h3 class="pmc_sec_title">Secondary outcomes</h3>
<section id="Sec43"><h4 class="pmc_sec_title">NMSS</h4>
<p id="Par49">The analysis did not demonstrate a statistically significant difference in the NMSS for patients receiving the treatment compared to those receiving a placebo (MD = − 2.31; 95% CI − 9.39 to 4.76; p = 0.52). There was no heterogeneity (I<sup>2</sup> = 42%, p = 0.18), and a random-effects model was employed (Fig. <a href="#Fig16" class="usa-link">16</a>).</p>
<figure class="fig xbox font-sm" id="Fig16"><h5 class="obj_head">Fig. 16.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig16_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/302e6f47877b/13098_2025_1888_Fig16_HTML.jpg" loading="lazy" id="MO16" height="140" width="784" alt="Fig. 16"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig16/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 2.1: GLP-1 receptor agonists vs. placebo, NMSS</p></figcaption></figure></section><section id="Sec44"><h4 class="pmc_sec_title">PDQ‐39</h4>
<p id="Par50">The meta-analysis (Fig. <a href="#Fig17" class="usa-link">17</a>) revealed no significant change in the PDQ-39 between the treatment group and the placebo group (MD = − 1.78; 95% CI − 5.01 to 1.46; p = 0.28).</p>
<figure class="fig xbox font-sm" id="Fig17"><h5 class="obj_head">Fig. 17.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig17_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/8bbd195b61d8/13098_2025_1888_Fig17_HTML.jpg" loading="lazy" id="MO17" height="160" width="784" alt="Fig. 17"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig17/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 2.2: GLP-1 receptor agonists vs. placebo, PDQ-39</p></figcaption></figure></section><section id="Sec45"><h4 class="pmc_sec_title">LED</h4>
<p id="Par51">Similarly to the other non-motor symptoms, the pooled analysis showed an insignificant improvement in the LED in the treatment groups compared to the placebo (MD = − 31.53; 95% CI − 116.96 to 53.91; p = 0.47) (Fig. <a href="#Fig18" class="usa-link">18</a>).</p>
<figure class="fig xbox font-sm" id="Fig18"><h5 class="obj_head">Fig. 18.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374370_13098_2025_1888_Fig18_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a34/12374370/3f882fe23e3e/13098_2025_1888_Fig18_HTML.jpg" loading="lazy" id="MO18" height="127" width="782" alt="Fig. 18"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig18/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis 2.3: GLP-1 receptor agonists vs. placebo, LED</p></figcaption></figure></section></section></section><section id="Sec46"><h2 class="pmc_sec_title">Discussion</h2>
<section id="Sec47"><h3 class="pmc_sec_title">Summary of main results</h3>
<p id="Par52">This meta-analysis evaluated the effects of GLP-1 receptor agonists on key clinical outcomes, specifically the MDS-UPDRS subscales (Parts III, IV, and II), along with the frequency of adverse events. We found statistically significant improvements in the MDS-UPDRS Part III ON medication subscale in subjects receiving GLP-1 receptor agonists compared to the placebo group in endpoints. Notably, the results from the trial by Meissner et al. were the only ones that, when excluded, altered the significance of the results [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. However, no significant improvements were observed in the MDS-UPDRS Parts II and IV. Regarding safety, the GLP-1 receptor agonists group reported a higher frequency of all adverse events, significantly in dyspepsia, vomiting, and constipation, with non-significant differences in diarrhea, headache, and fatigue.</p></section><section id="Sec48"><h3 class="pmc_sec_title">Context of our findings</h3>
<p id="Par53">Therapies for PD have been devised based on the principle that PD is underlined by a deficiency in dopamine within the striatum. Treatments included dopamine agonists that stimulate neuronal dopamine receptors, such as levodopa; monoamine oxidase-B (MAO-B) inhibitors that inhibit metabolism of dopamine in the brain, such as selegiline and rasagiline; and catechol-<em>O</em>-methyl transferase (COMT) inhibitors that inhibit degradation of levodopa in the periphery, such as entacapone and opicapone [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>].</p>
<p id="Par54">Problems in PD therapies include the short half-life and fluctuant plasma levels of levodopa, the precursor of dopamine [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]; variable effects of MAO-B [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]; and the short duration of entacapone and opicapone [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>], as well as other troubles that necessitated the search for a viable different option.</p>
<p id="Par55">The rationale behind the use of GLP-1 receptor agonists in the management of PD is supported by the fact that T2DM patients experience a more severe form of PD than non-diabetic patients. They show significantly more severe motor symptoms, greater total non-motor symptoms, poorer cognitive scores, and a greater need for greater amounts of dopaminergic medication. Moreover, over time, patients with T2DM have significantly faster progression of motor symptoms, worse depression scores, and are more likely to develop substantial gait impairment and mild cognitive impairment than patients without T2DM [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>, <a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>].</p>
<p id="Par56">GLP-1 receptor agonists’ potential therapeutic effects appear to target key pathological mechanisms of PD directly. Preclinical studies have shown that GLP-1 receptor activation reduces neuroinflammation by suppressing pro-inflammatory cytokines such as TNF-α and inhibiting glial cell activation [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. Additionally, these agents mitigate oxidative stress through upregulation of antioxidant pathways, including NRF2 (nuclear factor erythroid 2-related factor 2), enhance mitochondrial function, and reduce pathological α-synuclein aggregation [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>, <a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. These multifaceted mechanisms suggest that GLP-1 receptor agonists may offer disease-modifying benefits in PD, beyond their established metabolic effects.</p>
<p id="Par57">While previous studies have reported a reduced risk of developing PD in <em>diabetic patients</em> using GLP-1 receptor agonists, likely due to improved glucose metabolism and reduced neuroinflammatory burden, it is important to note that the trials assessing their efficacy in managing PD and included in our analysis applied a diagnosis of diabetes as an exclusion criterion. This creates a gap in the evidence. Future investigations should include diabetic populations with PD to properly assess the efficacy profile of GLP-1 receptor agonists and determine whether the observed improvement in the MDS-UPDRS Part III score (MD = − 2.88; p = 0.01) from our analysis is reproducible in such populations.</p>
<p id="Par58">Beyond the CNS, and in another diabetes-related disorder, GLP-1 receptor agonists have shown great promise in diabetic peripheral neuropathy (DPN), a common complication of diabetes marked by nerve damage caused by chronic hyperglycemia and oxidative stress. The metabolic homeostasis that GLP-1 receptor agonists can induce has even been suggested to “reverse” nerve morphological abnormalities in DPN [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. The mechanisms proposed to explain their benefits in peripheral nerves closely parallel those implicated in their neuroprotective effects in the brain [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>]. These parallels further support the need to investigate the therapeutic potential of GLP-1 receptor agonists in diabetic patients with PD, who may benefit from both central and peripheral neuroprotection.</p></section><section id="Sec49"><h3 class="pmc_sec_title">Agreements and disagreements with other studies or reviews</h3>
<p id="Par59">A similar Cochrane review was conducted in 2020, at a time when only two trials had been published investigating the role of GLP-1 receptor agonists in PD [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. However, that review did not pool the findings from these studies in a meta-analysis, which limits direct comparison with our results. Since then, additional trials have been published, further contributing to the growing body of evidence on the potential role of GLP-1 receptor agonists in PD management [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>–<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>].</p>
<p id="Par60">A more recent meta-analysis included the same number of trials as ours and reported similar findings with regard to motor symptoms, assessed by MDS-UPDRS Part III. However, our study provides a significantly more comprehensive evaluation. Notably, unlike Albuquerque and colleagues, our review included both published and ongoing studies, offering broader insights into the current landscape and future directions of GLP-1 receptor agonist research in PD. Additionally, our meta-analysis pooled a wider range of outcomes, encompassing not only motor symptoms but also safety outcomes, an aspect not addressed in their analysis. We evaluated six distinct gastrointestinal and systemic adverse events, which were designated as primary outcomes in our review. Furthermore, in our approach, we analyzed data at multiple time points (midpoints and endpoints), allowing a longitudinal assessment of efficacy that was not explored in previous reviews [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>].</p>
<p id="Par61">An earlier general systematic review on the neuroprotective role of GLP-1, which included both clinical and preclinical trials in PD, Alzheimer’s disease (AD), mood disorders, and other conditions, concluded—based on preclinical data—that GLP-1 has a substantial role in neuroprotection [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]. This was thought to occur through mechanisms such as the restoration of neurite outgrowth, increased neurotrophic factors, and strengthening of the blood–brain barrier. However, the clinical evidence included in that review was insufficient to draw conclusive interpretations about GLP-1’s potential in individuals with neurodegenerative diseases.</p>
<p id="Par62">In AD, some studies have suggested that the GLP-1 receptor agonist liraglutide may slow disease progression [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. However, the mechanisms behind these effects remain poorly understood. A recent systematic review assessing GLP-1 receptor agonists in AD found that, while these agents do not appear to significantly improve cognitive function via effects on amyloid-β and tau biomarkers, they may still offer metabolic and neuroprotective benefits [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>].</p>
<p id="Par63">In the context of amyotrophic lateral sclerosis (ALS), another neurodegenerative disorder, two recent cross-sectional case–control studies examined the role of metabolic biomarkers, including GLP-1, in the progression and pathogenesis of ALS [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. These studies notably found elevated levels of GLP-1 in ALS patients compared to healthy controls. However, GLP-1 showed insignificant correlations with all subscales of the ALS functional scale (ALSFRS-R), although a weak correlation was observed with the total ALSFRS-R score (r = 0.205; p = 0.032) [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. This suggests that while GLP-1 levels are altered in ALS, their clinical relevance to functional status remains uncertain.</p>
<p id="Par64">These mixed findings of GLP-1 and its receptor agonists research in neurodegenerative diseases underscore the complexity of their role, highlighting the need for further research to clarify their potential impact on the pathology and prognosis of such conditions.</p></section><section id="Sec50"><h3 class="pmc_sec_title">Limitations</h3>
<p id="Par65">Several limitations must be considered when interpreting the findings of this review. First, the sample sizes in the included trials were relatively small, which may have limited the power to detect significant differences in outcomes. Although all of the trials were randomized, some with small cohorts failed to fully balance baseline characteristics between experimental and control groups despite the randomization [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. Differences in baseline characteristics of trial arms may affect intervention response and disease progression [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>], potentially impacting or skewing the results of the trials.</p>
<p id="Par66">Additionally, the small sample sizes in the included studies led to some questionable observations. For instance, in two included trials, younger PD subjects in the placebo group exhibited greater and more rapid motor deterioration, as measured by the MDS-UPDRS Part III subscale, compared to their older counterparts [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. This contrasts with most PD literature, which suggests that younger patients generally have better compensatory resiliency and slower disease progression [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>–<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>]. However, due to the limited number of participants, plausible explanations for this observation remain unclear.</p>
<p id="Par67">Moreover, the self-administration of GLP-1 receptor agonists via subcutaneous injection in all of the included trials adds an element of uncertainty regarding the validity of the results. Noncompliance is a common issue with self-administered treatments. Additionally, the use of subcutaneous injections of GLP-1 receptor agonists via a pen may represent an unfamiliar and potentially challenging route of administration for some participants.</p>
<p id="Par68">Notably, none of the included trials investigated newer GLP-1 compounds such as tirzepatide, a dual GIP/GLP-1 receptor agonist, or semaglutide. These agents have demonstrated particular promise, with semaglutide showing a 40% reduction in AD risk in subjects with T2DM compared to other GLP-1 receptor agonists in a previous cohort study [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>]. This profile opens promising avenues for investigation as management strategies in neurodegenerative diseases, including PD.</p>
<p id="Par69">Another factor to consider when interpreting our results with caution is the inconsistency in the endpoints across the included studies, with follow-up periods ranging from 44 to 60 weeks [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>–<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. This variation in study duration may introduce inconsistency across the studies. In addition, this variability could introduce biases related to our selection of specific time points for data pooling, which affects the comparability of the studies [<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>].</p></section><section id="Sec51"><h3 class="pmc_sec_title">Strengths</h3>
<p id="Par70">Despite these limitations, this review benefits from several strengths. We conducted a thorough search of both published and gray literature to ensure the inclusion of all relevant clinical trials on this topic. Additionally, to minimize errors and bias, nearly every step of the review process was performed by at least two reviewers. Furthermore, rigorous methodological standards, including adherence to the Cochrane Handbook for Systematic Reviews, were followed to ensure robustness in our approach. For instance, we carefully addressed issues related to the unit of analysis, such as the multiple treatment arms in <em>McGarry 2024</em>, to avoid errors in the data synthesis process (see “<a href="#Sec18" class="usa-link">Unit of analysis issues</a>” section Unit of analysis issues) [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Unit of analysis problems are common in meta-analyses [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]. Moreover, four of the five included studies were of high quality, with a low risk of bias across most domains, which enhances the confidence in the validity of our findings.</p></section></section><section id="Sec52"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par71">Our analyses yielded inconclusive results regarding the effect of GLP-1 receptor agonists in PD treatment, primarily due to the limited number of trials and participants. Given the questionable observations in the studies and the unclear mechanisms of action, it is currently not recommended to use or attempt GLP-1 receptor agonists in clinical settings for PD outside of research contexts. Further double-blinded, placebo-controlled multicenter trials are needed to provide more definitive clinical insights. Larger sample sizes are crucial to account for baseline imbalances between study groups and to better elucidate the specific impact of GLP-1 receptor agonists on both the symptoms and progression of PD. Furthermore, the longest follow-up period in the included studies of our review was 60 weeks, which may not be sufficient for evaluating long-term effects in a disease as chronically progressive as PD. It is worth noting that one of the ongoing studies is planned to extend over a 4-year period, which may provide more comprehensive data on the long-term effects of GLP-1 receptor agonists. These future studies should address the uncertainties raised in previous evidence, particularly regarding the role of GLP-1 in disease progression, its mechanism of action, and its safety profile, to further clarify the potential of GLP-1 receptor agonists as a therapeutic option in PD.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>M.M.H: conceptualization, methodology, screening, analysis, and writing methods and discussion sections. H.A: hand search, data extraction, preparing tables, and writing introduction. O.H.A: screening, data extraction, risk of bias assessment, and analysis. R.H: screening, data extraction, preparing tables, and writing results section. Y.Z: screening, data extraction, and drafting introduction section. A.S.O: screening, data extraction, and searching for ongoing trials. A.K.H: supervision, and drafting discussion section.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>Data is provided within the manuscript.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par72">Ethical approval and informed consent were not required for this study, as it did not involve human participants or material.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par73">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20:385–97.
</cite> [<a href="https://doi.org/10.1016/S1474-4422(21)00030-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8185633/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33894193/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tolosa%20E,%20Garrido%20A,%20Scholz%20SW,%20Poewe%20W.%20Challenges%20in%20the%20diagnosis%20of%20Parkinson%E2%80%99s%20disease.%20Lancet%20Neurol.%202021;20:385%E2%80%9397." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–53.
</cite> [<a href="https://doi.org/10.1016/S1474-4422(18)30295-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6191528/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30287051/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?GBD%202016%20Parkinson%E2%80%99s%20Disease%20Collaborators.%20Global,%20regional,%20and%20national%20burden%20of%20Parkinson%E2%80%99s%20disease,%201990%E2%80%932016:%20a%20systematic%20analysis%20for%20the%20Global%20Burden%20of%20Disease%20Study%202016.%20Lancet%20Neurol.%202018;17:939%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Abou-Sleiman PM, Muqit MMK, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci. 2006;7:207–19.
</cite> [<a href="https://doi.org/10.1038/nrn1868" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16495942/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Abou-Sleiman%20PM,%20Muqit%20MMK,%20Wood%20NW.%20Expanding%20insights%20of%20mitochondrial%20dysfunction%20in%20Parkinson%E2%80%99s%20disease.%20Nat%20Rev%20Neurosci.%202006;7:207%E2%80%9319." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Kouli A, Torsney KM, Kuan W-L. Parkinson’s disease: etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson’s disease: pathogenesis and clinical aspects. Brisbane: Codon Publications; 2018.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/30702842/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kouli%20A,%20Torsney%20KM,%20Kuan%20W-L.%20Parkinson%E2%80%99s%20disease:%20etiology,%20neuropathology,%20and%20pathogenesis.%20In:%20Stoker%20TB,%20Greenland%20JC,%20editors.%20Parkinson%E2%80%99s%20disease:%20pathogenesis%20and%20clinical%20aspects.%20Brisbane:%20Codon%20Publications;%202018." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Dai C, Tan C, Zhao L, Liang Y, Liu G, Liu H, Zhong Y, Liu Z, Mo L, Liu X, Chen L. Glucose metabolism impairment in Parkinson’s disease. Brain Res Bull. 2023;199: 110672.
</cite> [<a href="https://doi.org/10.1016/j.brainresbull.2023.110672" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37210012/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dai%20C,%20Tan%20C,%20Zhao%20L,%20Liang%20Y,%20Liu%20G,%20Liu%20H,%20Zhong%20Y,%20Liu%20Z,%20Mo%20L,%20Liu%20X,%20Chen%20L.%20Glucose%20metabolism%20impairment%20in%20Parkinson%E2%80%99s%20disease.%20Brain%20Res%20Bull.%202023;199:%20110672." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Hong C-T, Chen K-Y, Wang W, Chiu J-Y, Wu D, Chao T-Y, Hu C-J, Chau K-YD, Bamodu OA. Insulin resistance promotes Parkinson’s disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells. 2020. 10.3390/cells9030740.
</cite> [<a href="https://doi.org/10.3390/cells9030740" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7140619/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32192190/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hong%20C-T,%20Chen%20K-Y,%20Wang%20W,%20Chiu%20J-Y,%20Wu%20D,%20Chao%20T-Y,%20Hu%20C-J,%20Chau%20K-YD,%20Bamodu%20OA.%20Insulin%20resistance%20promotes%20Parkinson%E2%80%99s%20disease%20through%20aberrant%20expression%20of%20%CE%B1-synuclein,%20mitochondrial%20dysfunction,%20and%20deregulation%20of%20the%20polo-like%20kinase%202%20signaling.%20Cells.%202020.%2010.3390/cells9030740." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Wang R, Shih LC. Parkinson’s disease - current treatment. Curr Opin Neurol. 2023;36:302–8.
</cite> [<a href="https://doi.org/10.1097/WCO.0000000000001166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37366218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20R,%20Shih%20LC.%20Parkinson%E2%80%99s%20disease%20-%20current%20treatment.%20Curr%20Opin%20Neurol.%202023;36:302%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Cullinane PW, de Pablo Fernandez E, König A, Outeiro TF, Jaunmuktane Z, Warner TT. Type 2 diabetes and parkinson’s disease: a focused review of current concepts. Mov Disord. 2023;38:162–77.
</cite> [<a href="https://doi.org/10.1002/mds.29298" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36567671/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cullinane%20PW,%20de%20Pablo%20Fernandez%20E,%20K%C3%B6nig%20A,%20Outeiro%20TF,%20Jaunmuktane%20Z,%20Warner%20TT.%20Type%202%20diabetes%20and%20parkinson%E2%80%99s%20disease:%20a%20focused%20review%20of%20current%20concepts.%20Mov%20Disord.%202023;38:162%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, Ludvigsson JF. Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study. Mov Disord. 2016;31:1422–3.
</cite> [<a href="https://doi.org/10.1002/mds.26734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27431803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Svenningsson%20P,%20Wirdefeldt%20K,%20Yin%20L,%20Fang%20F,%20Markaki%20I,%20Efendic%20S,%20Ludvigsson%20JF.%20Reduced%20incidence%20of%20Parkinson%E2%80%99s%20disease%20after%20dipeptidyl%20peptidase-4%20inhibitors-a%20nationwide%20case-control%20study.%20Mov%20Disord.%202016;31:1422%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Michailidis M, Moraitou D, Tata DA, Kalinderi K, Papamitsou T, Papaliagkas V. Alzheimer’s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer’s disease and type 2 diabetes. Int J Mol Sci. 2022. 10.3390/ijms23052687.
</cite> [<a href="https://doi.org/10.3390/ijms23052687" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8910482/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35269827/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Michailidis%20M,%20Moraitou%20D,%20Tata%20DA,%20Kalinderi%20K,%20Papamitsou%20T,%20Papaliagkas%20V.%20Alzheimer%E2%80%99s%20disease%20as%20type%203%20diabetes:%20common%20pathophysiological%20mechanisms%20between%20Alzheimer%E2%80%99s%20disease%20and%20type%202%20diabetes.%20Int%20J%20Mol%20Sci.%202022.%2010.3390/ijms23052687." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Zhang Y, Chen Y, Li L, Hölscher C. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model. Behav Brain Res. 2015;293:107–13.
</cite> [<a href="https://doi.org/10.1016/j.bbr.2015.07.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26187689/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Y,%20Chen%20Y,%20Li%20L,%20H%C3%B6lscher%20C.%20Neuroprotective%20effects%20of%20(Val8)GLP-1-Glu-PAL%20in%20the%20MPTP%20Parkinson%E2%80%99s%20disease%20mouse%20model.%20Behav%20Brain%20Res.%202015;293:107%E2%80%9313." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation. 2008;5:19.
</cite> [<a href="https://doi.org/10.1186/1742-2094-5-19" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2426681/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18492290/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Harkavyi%20A,%20Abuirmeileh%20A,%20Lever%20R,%20Kingsbury%20AE,%20Biggs%20CS,%20Whitton%20PS.%20Glucagon-like%20peptide%201%20receptor%20stimulation%20reverses%20key%20deficits%20in%20distinct%20rodent%20models%20of%20Parkinson%E2%80%99s%20disease.%20J%20Neuroinflammation.%202008;5:19." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel J-C, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Aβ oligomers. J Clin Invest. 2012;122:1339–53.
</cite> [<a href="https://doi.org/10.1172/JCI57256" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3314445/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22476196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bomfim%20TR,%20Forny-Germano%20L,%20Sathler%20LB,%20Brito-Moreira%20J,%20Houzel%20J-C,%20Decker%20H,%20Silverman%20MA,%20Kazi%20H,%20Melo%20HM,%20McClean%20PL,%20Holscher%20C,%20Arnold%20SE,%20Talbot%20K,%20Klein%20WL,%20Munoz%20DP,%20Ferreira%20ST,%20De%20Felice%20FG.%20An%20anti-diabetes%20agent%20protects%20the%20mouse%20brain%20from%20defective%20insulin%20signaling%20caused%20by%20Alzheimer%E2%80%99s%20disease-%20associated%20A%CE%B2%20oligomers.%20J%20Clin%20Invest.%202012;122:1339%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.
</cite> [<a href="https://doi.org/10.1016/j.ijsu.2021.105906" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33789826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Page%20MJ,%20McKenzie%20JE,%20Bossuyt%20PM,%20Boutron%20I,%20Hoffmann%20TC,%20Mulrow%20CD,%20Shamseer%20L,%20Tetzlaff%20JM,%20Akl%20EA,%20Brennan%20SE,%20Chou%20R,%20Glanville%20J,%20Grimshaw%20JM,%20Hr%C3%B3bjartsson%20A,%20Lalu%20MM,%20Li%20T,%20Loder%20EW,%20Mayo-Wilson%20E,%20McDonald%20S,%20McGuinness%20LA,%20Moher%20D.%20The%20PRISMA%202020%20statement:%20an%20updated%20guideline%20for%20reporting%20systematic%20reviews.%20Int%20J%20Surg.%202021;88:%20105906." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane; 2024<em>.</em></cite>
</li>
<li id="CR16">
<span class="label">16.</span><cite>Hogg E, Wu T, Bresee C, Wertheimer J, Malatt C, Tan E, Pomeroy H, Nuno M, Wyse R &amp; Tagliati M. A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson’s Disease. SSRN Journal; 2022.</cite>
</li>
<li id="CR17">
<span class="label">17.</span><cite>Li T, Higgins JPT, Deeks JJ. Chapter 5: Collecting data [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org/handbook</cite>
</li>
<li id="CR18">
<span class="label">18.</span><cite>McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org/handbook.</cite>
</li>
<li id="CR19">
<span class="label">19.</span><cite>Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738–50.
</cite> [<a href="https://doi.org/10.1002/mds.10473" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12815652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Movement%20Disorder%20Society%20Task%20Force%20on%20Rating%20Scales%20for%20Parkinson%E2%80%99s%20Disease.%20The%20Unified%20Parkinson%E2%80%99s%20Disease%20Rating%20Scale%20(UPDRS):%20status%20and%20recommendations.%20Mov%20Disord.%202003;18:738%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Sjödahl Hammarlund C, Nilsson MH, Hagell P. Measuring outcomes in Parkinson’s disease: a multi-perspective concept mapping study. Qual Life Res. 2012;21:453–63.
</cite> [<a href="https://doi.org/10.1007/s11136-011-9995-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21870190/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sj%C3%B6dahl%20Hammarlund%20C,%20Nilsson%20MH,%20Hagell%20P.%20Measuring%20outcomes%20in%20Parkinson%E2%80%99s%20disease:%20a%20multi-perspective%20concept%20mapping%20study.%20Qual%20Life%20Res.%202012;21:453%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, Noel-Storr A, Paynter R, Rader T, Thomas J, Wieland LS. Chapter 4: Searching for and selecting studies [last updated March 2025]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5.1 Cochrane; 2025. cochrane.org/handbook.</cite>
</li>
<li id="CR22">
<span class="label">22.</span><cite>Muka T, Glisic M, Milic J, Verhoog S, Bohlius J, Bramer W, Chowdhury R, Franco OH. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol. 2020;35:49–60.
</cite> [<a href="https://doi.org/10.1007/s10654-019-00576-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31720912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Muka%20T,%20Glisic%20M,%20Milic%20J,%20Verhoog%20S,%20Bohlius%20J,%20Bramer%20W,%20Chowdhury%20R,%20Franco%20OH.%20A%2024-step%20guide%20on%20how%20to%20design,%20conduct,%20and%20successfully%20publish%20a%20systematic%20review%20and%20meta-analysis%20in%20medical%20research.%20Eur%20J%20Epidemiol.%202020;35:49%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>EndNote - Citation &amp; Reference Management Tool. <a href="https://endnote.com/?srsltid=AfmBOoqB-MAtazd1KSYVBrKyYu8mD4vpDWwRnu5cgLBjM45y8rIJKIwM" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://endnote.com/?srsltid=AfmBOoqB-MAtazd1KSYVBrKyYu8mD4vpDWwRnu5cgLBjM45y8rIJKIwM</a></cite>
</li>
<li id="CR24">
<span class="label">24.</span><cite>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
</cite> [<a href="https://doi.org/10.1186/s13643-016-0384-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5139140/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27919275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ouzzani%20M,%20Hammady%20H,%20Fedorowicz%20Z,%20Elmagarmid%20A.%20Rayyan-a%20web%20and%20mobile%20app%20for%20systematic%20reviews.%20Syst%20Rev.%202016;5:210." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>“automeris.io: Computer vision assisted data extraction from charts using WebPlotDigitizer. <a href="https://automeris.io/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://automeris.io/</a>. Accessed 25 Aug 2024.</cite>
</li>
<li id="CR26">
<span class="label">26.</span><cite>"Meta-Analysis Accelerator | Your Meta-Analysis Conversion Tool. <a href="https://meta-converter.com" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://meta-converter.com</a></cite>
</li>
<li id="CR27">
<span class="label">27.</span><cite>Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–75.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(17)31585-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5831666/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28781108/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Athauda%20D,%20Maclagan%20K,%20Skene%20SS,%20Bajwa-Joseph%20M,%20Letchford%20D,%20Chowdhury%20K,%20Hibbert%20S,%20Budnik%20N,%20Zampedri%20L,%20Dickson%20J,%20Li%20Y,%20Aviles-Olmos%20I,%20Warner%20TT,%20Limousin%20P,%20Lees%20AJ,%20Greig%20NH,%20Tebbs%20S,%20Foltynie%20T.%20Exenatide%20once%20weekly%20versus%20placebo%20in%20Parkinson%E2%80%99s%20disease:%20a%20randomised,%20double-blind,%20placebo-controlled%20trial.%20Lancet.%202017;390:1664%E2%80%9375." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest. 2013;123:2730–6.
</cite> [<a href="https://doi.org/10.1172/JCI68295" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3668846/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23728174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Aviles-Olmos%20I,%20Dickson%20J,%20Kefalopoulou%20Z,%20Djamshidian%20A,%20Ell%20P,%20Soderlund%20T,%20Whitton%20P,%20Wyse%20R,%20Isaacs%20T,%20Lees%20A,%20Limousin%20P,%20Foltynie%20T.%20Exenatide%20and%20the%20treatment%20of%20patients%20with%20Parkinson%E2%80%99s%20disease.%20J%20Clin%20Invest.%202013;123:2730%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Malatt C, Wu T, Bresee C, Hogg E, Wertheimer J, Tan E, Pomeroy H, Obialisi G, Tagliati M. Liraglutide improves non-motor function and activities of daily living in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial (P9–11.005). Neurology. 2022. 10.1212/WNL.98.18_supplement.3068.</cite> [<a href="https://scholar.google.com/scholar_lookup?Malatt%20C,%20Wu%20T,%20Bresee%20C,%20Hogg%20E,%20Wertheimer%20J,%20Tan%20E,%20Pomeroy%20H,%20Obialisi%20G,%20Tagliati%20M.%20Liraglutide%20improves%20non-motor%20function%20and%20activities%20of%20daily%20living%20in%20patients%20with%20Parkinson%E2%80%99s%20disease:%20a%20randomized,%20double-blind,%20placebo-controlled%20trial%20(P9%E2%80%9311.005).%20Neurology.%202022.%2010.1212/WNL.98.18_supplement.3068." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Kieburtz K. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23:37–45.
</cite> [<a href="https://doi.org/10.1016/S1474-4422(23)00378-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38101901/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McGarry%20A,%20Rosanbalm%20S,%20Leinonen%20M,%20Olanow%20CW,%20To%20D,%20Bell%20A,%20Lee%20D,%20Chang%20J,%20Dubow%20J,%20Dhall%20R,%20Burdick%20D,%20Parashos%20S,%20Feuerstein%20J,%20Quinn%20J,%20Pahwa%20R,%20Afshari%20M,%20Ramirez-Zamora%20A,%20Chou%20K,%20Tarakad%20A,%20Luca%20C,%20Kieburtz%20K.%20Safety,%20tolerability,%20and%20efficacy%20of%20NLY01%20in%20early%20untreated%20Parkinson%E2%80%99s%20disease:%20a%20randomised,%20double-blind,%20placebo-controlled%20trial.%20Lancet%20Neurol.%202024;23:37%E2%80%9345." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto J-L, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol J-C, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, LIXIPARK Study Group. Trial of lixisenatide in early parkinson’s disease. N Engl J Med. 2024;390:1176–85.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2312323" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38598572/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Meissner%20WG,%20Remy%20P,%20Giordana%20C,%20Malt%C3%AAte%20D,%20Derkinderen%20P,%20Hou%C3%A9to%20J-L,%20Anheim%20M,%20Benatru%20I,%20Boraud%20T,%20Brefel-Courbon%20C,%20Carri%C3%A8re%20N,%20Catala%20H,%20Colin%20O,%20Corvol%20J-C,%20Damier%20P,%20Dellapina%20E,%20Devos%20D,%20Drapier%20S,%20Fabbri%20M,%20Ferrier%20V,%20LIXIPARK%20Study%20Group.%20Trial%20of%20lixisenatide%20in%20early%20parkinson%E2%80%99s%20disease.%20N%20Engl%20J%20Med.%202024;390:1176%E2%80%9385." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.
</cite> [<a href="https://doi.org/10.1136/bmj.l4898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31462531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sterne%20JAC,%20Savovi%C4%87%20J,%20Page%20MJ,%20Elbers%20RG,%20Blencowe%20NS,%20Boutron%20I,%20Cates%20CJ,%20Cheng%20H-Y,%20Corbett%20MS,%20Eldridge%20SM,%20Emberson%20JR,%20Hern%C3%A1n%20MA,%20Hopewell%20S,%20Hr%C3%B3bjartsson%20A,%20Junqueira%20DR,%20J%C3%BCni%20P,%20Kirkham%20JJ,%20Lasserson%20T,%20Li%20T,%20McAleenan%20A,%20Higgins%20JPT.%20RoB%202:%20a%20revised%20tool%20for%20assessing%20risk%20of%20bias%20in%20randomised%20trials.%20BMJ.%202019;366:%20l4898." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Higgins JPT, Li T, Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org/handbook.</cite>
</li>
<li id="CR34">
<span class="label">34.</span><cite>Safety and Efficacy of Liraglutide in Parkinson’s Disease. Available at: <a href="https://www.clinicaltrials.gov/study/NCT02953665?cond=Parkinson%27s%20Disease&amp;term=glp-1&amp;rank=10" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.clinicaltrials.gov/study/NCT02953665?cond=Parkinson%27s%20Disease&amp;term=glp-1&amp;rank=10</a></cite>
</li>
<li id="CR35">
<span class="label">35.</span><cite>The Cochrane Collaboration. Review Manager (RevMan)[computerprogram]. Version 5.4. 2020. <a href="https://login.cochrane.org/realms/cochrane/protocol/openid-connect/auth?client_id=revman-web&amp;redirect_uri=https%3A%2F%2Frevman.cochrane.org&amp;response_type=code&amp;scope=openid%20profile&amp;nonce=8ccf28f5aeff2e02c6dfb482c52de44befKjVOtjQ&amp;state=6d9731f6d393efb414301a963b42ed8ecajw3WtuZ&amp;code_challenge=M3yCEQMDg20WA-gKqE_CUCWqIa8q0ZUC2cMWkx-ucsw&amp;code_challenge_method=S256" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://login.cochrane.org/realms/cochrane/protocol/openid-connect/auth?client_id=revman-web&amp;redirect_uri=https%3A%2F%2Frevman.cochrane.org&amp;response_type=code&amp;scope=openid%20profile&amp;nonce=8ccf28f5aeff2e02c6dfb482c52de44befKjVOtjQ&amp;state=6d9731f6d393efb414301a963b42ed8ecajw3WtuZ&amp;code_challenge=M3yCEQMDg20WA-gKqE_CUCWqIa8q0ZUC2cMWkx-ucsw&amp;code_challenge_method=S256</a></cite>
</li>
<li id="CR36">
<span class="label">36.</span><cite>Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, Chowdhury K, Aviles-Olmos I, Limousin P, Foltynie T. What effects might Exenatide have on non-motor symptoms in Parkinson’s disease: a post hoc analysis. J Parkinsons Dis. 2018;8:247–58.
</cite> [<a href="https://doi.org/10.3233/JPD-181329" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29843254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Athauda%20D,%20Maclagan%20K,%20Budnik%20N,%20Zampedri%20L,%20Hibbert%20S,%20Skene%20SS,%20Chowdhury%20K,%20Aviles-Olmos%20I,%20Limousin%20P,%20Foltynie%20T.%20What%20effects%20might%20Exenatide%20have%20on%20non-motor%20symptoms%20in%20Parkinson%E2%80%99s%20disease:%20a%20post%20hoc%20analysis.%20J%20Parkinsons%20Dis.%202018;8:247%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis. 2014;4:337–44.
</cite> [<a href="https://doi.org/10.3233/JPD-140364" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24662192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Aviles-Olmos%20I,%20Dickson%20J,%20Kefalopoulou%20Z,%20Djamshidian%20A,%20Kahan%20J,%20Ell%20P,%20Whitton%20P,%20Wyse%20R,%20Isaacs%20T,%20Lees%20A,%20Limousin%20P,%20Foltynie%20T.%20Motor%20and%20cognitive%20advantages%20persist%2012%20months%20after%20exenatide%20exposure%20in%20Parkinson%E2%80%99s%20disease.%20J%20Parkinsons%20Dis.%202014;4:337%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, Chowdhury K, Skene SS, Limousin P, Foltynie T. Post hoc analysis of the Exenatide-PD trial-factors that predict response. Eur J Neurosci. 2019;49:410–21.
</cite> [<a href="https://doi.org/10.1111/ejn.14096" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30070753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Athauda%20D,%20Maclagan%20K,%20Budnik%20N,%20Zampedri%20L,%20Hibbert%20S,%20Aviles-Olmos%20I,%20Chowdhury%20K,%20Skene%20SS,%20Limousin%20P,%20Foltynie%20T.%20Post%20hoc%20analysis%20of%20the%20Exenatide-PD%20trial-factors%20that%20predict%20response.%20Eur%20J%20Neurosci.%202019;49:410%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Athauda D, Wyse R, Brundin P, Foltynie T. Is exenatide a treatment for Parkinson’s disease? J Parkinsons Dis. 2017;7:451–8.
</cite> [<a href="https://doi.org/10.3233/JPD-171192" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28777758/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Athauda%20D,%20Wyse%20R,%20Brundin%20P,%20Foltynie%20T.%20Is%20exenatide%20a%20treatment%20for%20Parkinson%E2%80%99s%20disease?%20J%20Parkinsons%20Dis.%202017;7:451%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Athauda D, Budnik N, Chowdhury K, Skene S, Foltynie T. The effect of exenatide on specific non-motor symptoms in Parkinson’s disease—a post-hoc analysis. In: European Journal of Neurology. Issue S2 edition. Vol. 25. Abstracts of the 4th congress of the European academy of neurology, Lisbon, Portugal, 2018, 2018:309.</cite>
</li>
<li id="CR41">
<span class="label">41.</span><cite>Foltynie T, Aviles-Olmos I. Exenatide as a potential treatment for patients with Parkinson’s disease: first steps into the clinic. Alzheimers Dement. 2014;10:S38-46.
</cite> [<a href="https://doi.org/10.1016/j.jalz.2013.12.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24529524/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Foltynie%20T,%20Aviles-Olmos%20I.%20Exenatide%20as%20a%20potential%20treatment%20for%20patients%20with%20Parkinson%E2%80%99s%20disease:%20first%20steps%20into%20the%20clinic.%20Alzheimers%20Dement.%202014;10:S38-46." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Aviles-Olmos I, Dickson J, Kefalopoupou Z, Djamshidian A, Kahan J, Ell P, et al. Exenatide and non motor symptoms In Parkinson’s disease (PD) [abstract]. In: Movement Disorders. Vol. 29 Suppl 1 6:12. 2014.</cite>
</li>
<li id="CR43">
<span class="label">43.</span><cite>Aviles-Olmos I &amp; Kefalopoulou Z (2012) Aviles-Olmos I, Kefalopoulou Z, Djamshidian A, Limousin P, Dickson J, Lees A, et al. An open label, single site, 12 month, phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (exenatide) in the treatment of patients with moderate severity Parkinson’s disease [abstract]. Movement Disorders 2012;27(Suppl 1:343). <em>Movement …</em>.</cite>
</li>
<li id="CR44">
<span class="label">44.</span><cite>Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Exenatide and motor symptoms in Parkinson’s disease (PD) [abstract]. In: Movement Disorders. Vol. 29 Suppl 1:611; 2014.</cite>
</li>
<li id="CR45">
<span class="label">45.</span><cite>Effects of Exenatide on Motor Function and the Brain. ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT03456687" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03456687</a>. <a href="https://www.clinicaltrials.gov/study/NCT03456687?cond=Parkinson%27s%20Disease&amp;term=glp-1&amp;rank=1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.clinicaltrials.gov/study/NCT03456687?cond=Parkinson%27s%20Disease&amp;term=glp-1&amp;rank=1</a></cite>
</li>
<li id="CR46">
<span class="label">46.</span><cite>Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson’s Disease (Exenatide-PD3). ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT04232969" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04232969</a>. <a href="https://clinicaltrials.gov/study/NCT04232969" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT04232969</a></cite>
</li>
<li id="CR47">
<span class="label">47.</span><cite>SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson’s Disease. ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT04269642" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04269642</a>. <a href="https://clinicaltrials.gov/study/NCT04269642?term=AREA%5BConditionSearch%5D(Neurodegenerative%20Diseases)%20AND%20AREA%5BInterventionSearch%5D(exendin-4)&amp;rank=9" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT04269642?term=AREA%5BConditionSearch%5D(Neurodegenerative%20Diseases)%20AND%20AREA%5BInterventionSearch%5D(exendin-4)&amp;rank=9</a></cite>
</li>
<li id="CR48">
<span class="label">48.</span><cite>GLP1R in Parkinson’s Disease (GIPD). ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT03659682" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03659682</a>. <a href="https://clinicaltrials.gov/study/NCT03659682" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT03659682</a></cite>
</li>
<li id="CR49">
<span class="label">49.</span><cite>Exenatide Treatment in Parkinson’s Disease. ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT04305002" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04305002</a>. <a href="https://clinicaltrials.gov/study/NCT04305002" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT04305002</a></cite>
</li>
<li id="CR50">
<span class="label">50.</span><cite>Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent advances in drug therapy for Parkinson’s disease. Intern Med. 2023;62:33–42.
</cite> [<a href="https://doi.org/10.2169/internalmedicine.8940-21" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9876715/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35110492/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Murakami%20H,%20Shiraishi%20T,%20Umehara%20T,%20Omoto%20S,%20Iguchi%20Y.%20Recent%20advances%20in%20drug%20therapy%20for%20Parkinson%E2%80%99s%20disease.%20Intern%20Med.%202023;62:33%E2%80%9342." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Murata M, Mihara M, Hasegawa K, Jeon B, Tsai C-H, Nishikawa N, Oeda T, Yokoyama M, Robieson WZ, Ryman D, Eaton S, Chatamra K, Benesh J. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients. NPJ Parkinsons Dis. 2016;2: 16020.
</cite> [<a href="https://doi.org/10.1038/npjparkd.2016.20" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5516619/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28725701/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Murata%20M,%20Mihara%20M,%20Hasegawa%20K,%20Jeon%20B,%20Tsai%20C-H,%20Nishikawa%20N,%20Oeda%20T,%20Yokoyama%20M,%20Robieson%20WZ,%20Ryman%20D,%20Eaton%20S,%20Chatamra%20K,%20Benesh%20J.%20Efficacy%20and%20safety%20of%20levodopa-carbidopa%20intestinal%20gel%20from%20a%20study%20in%20Japanese,%20Taiwanese,%20and%20Korean%20advanced%20Parkinson%E2%80%99s%20disease%20patients.%20NPJ%20Parkinsons%20Dis.%202016;2:%2016020." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Takeda A, Takahashi R, Tsuboi Y, Nomoto M, Maeda T, Nishimura A, Yoshida K, Hattori N. Randomized, controlled study of opicapone in Japanese Parkinson’s patients with motor fluctuations. Mov Disord. 2021;36:415–23.
</cite> [<a href="https://doi.org/10.1002/mds.28322" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7983910/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33073879/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Takeda%20A,%20Takahashi%20R,%20Tsuboi%20Y,%20Nomoto%20M,%20Maeda%20T,%20Nishimura%20A,%20Yoshida%20K,%20Hattori%20N.%20Randomized,%20controlled%20study%20of%20opicapone%20in%20Japanese%20Parkinson%E2%80%99s%20patients%20with%20motor%20fluctuations.%20Mov%20Disord.%202021;36:415%E2%80%9323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, Vijiaratnam N, Girges C, Ben-Shlomo Y, Ismail K, Morris H, Grosset D, Foltynie T, Gandhi S. The impact of type 2 diabetes in Parkinson’s disease. Mov Disord. 2022;37:1612–23.
</cite> [<a href="https://doi.org/10.1002/mds.29122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9543753/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35699244/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Athauda%20D,%20Evans%20J,%20Wernick%20A,%20Virdi%20G,%20Choi%20ML,%20Lawton%20M,%20Vijiaratnam%20N,%20Girges%20C,%20Ben-Shlomo%20Y,%20Ismail%20K,%20Morris%20H,%20Grosset%20D,%20Foltynie%20T,%20Gandhi%20S.%20The%20impact%20of%20type%202%20diabetes%20in%20Parkinson%E2%80%99s%20disease.%20Mov%20Disord.%202022;37:1612%E2%80%9323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Komici K, Femminella GD, Bencivenga L, Rengo G, Pagano G. Diabetes mellitus and Parkinson’s disease: a systematic review and meta-analyses. J Parkinsons Dis. 2021;11:1585–96.
</cite> [<a href="https://doi.org/10.3233/JPD-212725" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34486987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Komici%20K,%20Femminella%20GD,%20Bencivenga%20L,%20Rengo%20G,%20Pagano%20G.%20Diabetes%20mellitus%20and%20Parkinson%E2%80%99s%20disease:%20a%20systematic%20review%20and%20meta-analyses.%20J%20Parkinsons%20Dis.%202021;11:1585%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Kalinderi K, Papaliagkas V, Fidani L. GLP-1 receptor agonists: a new treatment in Parkinson’s disease. Int J Mol Sci. 2024. 10.3390/ijms25073812.
</cite> [<a href="https://doi.org/10.3390/ijms25073812" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11011817/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38612620/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kalinderi%20K,%20Papaliagkas%20V,%20Fidani%20L.%20GLP-1%20receptor%20agonists:%20a%20new%20treatment%20in%20Parkinson%E2%80%99s%20disease.%20Int%20J%20Mol%20Sci.%202024.%2010.3390/ijms25073812." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci. 2003;23:2939–46.
</cite> [<a href="https://doi.org/10.1523/JNEUROSCI.23-07-02939.2003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6742071/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12684481/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yamamoto%20H,%20Kishi%20T,%20Lee%20CE,%20Choi%20BJ,%20Fang%20H,%20Hollenberg%20AN,%20Drucker%20DJ,%20Elmquist%20JK.%20Glucagon-like%20peptide-1-responsive%20catecholamine%20neurons%20in%20the%20area%20postrema%20link%20peripheral%20glucagon-like%20peptide-1%20with%20central%20autonomic%20control%20sites.%20J%20Neurosci.%202003;23:2939%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Elbassuoni EA, Ahmed RF. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson’s with pre-existing diabetes. Neurochem Int. 2019;131: 104583.
</cite> [<a href="https://doi.org/10.1016/j.neuint.2019.104583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31654678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Elbassuoni%20EA,%20Ahmed%20RF.%20Mechanism%20of%20the%20neuroprotective%20effect%20of%20GLP-1%20in%20a%20rat%20model%20of%20Parkinson%E2%80%99s%20with%20pre-existing%20diabetes.%20Neurochem%20Int.%202019;131:%20104583." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Dhanapalaratnam R, Issar T, Lee ATK, Poynten AM, Milner K-L, Kwai NCG, Krishnan AV. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia. 2024;67:561–6.
</cite> [<a href="https://doi.org/10.1007/s00125-023-06072-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38189936/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dhanapalaratnam%20R,%20Issar%20T,%20Lee%20ATK,%20Poynten%20AM,%20Milner%20K-L,%20Kwai%20NCG,%20Krishnan%20AV.%20Glucagon-like%20peptide-1%20receptor%20agonists%20reverse%20nerve%20morphological%20abnormalities%20in%20diabetic%20peripheral%20neuropathy.%20Diabetologia.%202024;67:561%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Liu C, Wu T, Ren N. Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy. Front Endocrinol (Lausanne). 2023;14: 1268619.
</cite> [<a href="https://doi.org/10.3389/fendo.2023.1268619" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10836428/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38313844/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20C,%20Wu%20T,%20Ren%20N.%20Glucagon-like%20peptide-1%20receptor%20agonists%20for%20the%20management%20of%20diabetic%20peripheral%20neuropathy.%20Front%20Endocrinol%20(Lausanne).%202023;14:%201268619." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, Emsley HC. GLP-1 receptor agonists for Parkinson’s disease. Cochrane Database Syst Rev. 2020;7: CD012990.
</cite> [<a href="https://doi.org/10.1002/14651858.CD012990.pub2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7390475/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32700772/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mulvaney%20CA,%20Duarte%20GS,%20Handley%20J,%20Evans%20DJ,%20Menon%20S,%20Wyse%20R,%20Emsley%20HC.%20GLP-1%20receptor%20agonists%20for%20Parkinson%E2%80%99s%20disease.%20Cochrane%20Database%20Syst%20Rev.%202020;7:%20CD012990." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>de Albuquerque MB, Nunes LEDB, de Oliveira Maldonado JV, Melo Ferreira DG, Margato MM, Rabelo LV, Valença MM, Oliveira Cordeiro LH. GLP-1 receptor agonists for Parkinson’s disease: an updated meta-analysis. Parkinsonism Relat Disord. 2025;130: 107220.
</cite> [<a href="https://doi.org/10.1016/j.parkreldis.2024.107220" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39642803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?de%20Albuquerque%20MB,%20Nunes%20LEDB,%20de%20Oliveira%20Maldonado%20JV,%20Melo%20Ferreira%20DG,%20Margato%20MM,%20Rabelo%20LV,%20Valen%C3%A7a%20MM,%20Oliveira%20Cordeiro%20LH.%20GLP-1%20receptor%20agonists%20for%20Parkinson%E2%80%99s%20disease:%20an%20updated%20meta-analysis.%20Parkinsonism%20Relat%20Disord.%202025;130:%20107220." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Erbil D, Eren CY, Demirel C, Küçüker MU, Solaroğlu I, Eser HY. GLP-1’s role in neuroprotection: a systematic review. Brain Inj. 2019;33:734–819.
</cite> [<a href="https://doi.org/10.1080/02699052.2019.1587000" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30938196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Erbil%20D,%20Eren%20CY,%20Demirel%20C,%20K%C3%BC%C3%A7%C3%BCker%20MU,%20Solaro%C4%9Flu%20I,%20Eser%20HY.%20GLP-1%E2%80%99s%20role%20in%20neuroprotection:%20a%20systematic%20review.%20Brain%20Inj.%202019;33:734%E2%80%93819." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL. Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease. Behav Brain Res. 2019;356:271–8.
</cite> [<a href="https://doi.org/10.1016/j.bbr.2018.08.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30099030/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Watson%20KT,%20Wroolie%20TE,%20Tong%20G,%20Foland-Ross%20LC,%20Frangou%20S,%20Singh%20M,%20McIntyre%20RS,%20Roat-Shumway%20S,%20Myoraku%20A,%20Reiss%20AL,%20Rasgon%20NL.%20Neural%20correlates%20of%20liraglutide%20effects%20in%20persons%20at%20risk%20for%20Alzheimer%E2%80%99s%20disease.%20Behav%20Brain%20Res.%202019;356:271%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Liang Y, Doré V, Rowe CC, Krishnadas N. Clinical evidence for GLP-1 receptor agonists in Alzheimer’s disease: a systematic review. ADR. 2024;8:777–89.</cite> [<a href="https://doi.org/10.3233/ADR-230181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11091751/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38746639/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liang%20Y,%20Dor%C3%A9%20V,%20Rowe%20CC,%20Krishnadas%20N.%20Clinical%20evidence%20for%20GLP-1%20receptor%20agonists%20in%20Alzheimer%E2%80%99s%20disease:%20a%20systematic%20review.%20ADR.%202024;8:777%E2%80%9389." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Li J-Y, Cui L-Y, Sun X-H, Shen D-C, Yang X-Z, Liu Q, Liu M-S. Alterations in metabolic biomarkers and their potential role in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2022;9:1027–38.
</cite> [<a href="https://doi.org/10.1002/acn3.51580" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9268864/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35584112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20J-Y,%20Cui%20L-Y,%20Sun%20X-H,%20Shen%20D-C,%20Yang%20X-Z,%20Liu%20Q,%20Liu%20M-S.%20Alterations%20in%20metabolic%20biomarkers%20and%20their%20potential%20role%20in%20amyotrophic%20lateral%20sclerosis.%20Ann%20Clin%20Transl%20Neurol.%202022;9:1027%E2%80%9338." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Moțățăianu A, Mănescu IB, Șerban G, Bărcuțean L, Ion V, Bălașa R, Andone S. Exploring the role of metabolic hormones in amyotrophic lateral sclerosis. Int J Mol Sci. 2024. 10.3390/ijms25105059.
</cite> [<a href="https://doi.org/10.3390/ijms25105059" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11121721/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38791099/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mo%C8%9B%C4%83%C8%9B%C4%83ianu%20A,%20M%C4%83nescu%20IB,%20%C8%98erban%20G,%20B%C4%83rcu%C8%9Bean%20L,%20Ion%20V,%20B%C4%83la%C8%99a%20R,%20Andone%20S.%20Exploring%20the%20role%20of%20metabolic%20hormones%20in%20amyotrophic%20lateral%20sclerosis.%20Int%20J%20Mol%20Sci.%202024.%2010.3390/ijms25105059." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003;60:529–33.
</cite> [<a href="https://doi.org/10.1001/archneur.60.4.529" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12707066/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Diederich%20NJ,%20Moore%20CG,%20Leurgans%20SE,%20Chmura%20TA,%20Goetz%20CG.%20Parkinson%20disease%20with%20old-age%20onset:%20a%20comparative%20study%20with%20subjects%20with%20middle-age%20onset.%20Arch%20Neurol.%202003;60:529%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson’s disease. Neurology. 1989;39:1187–90.
</cite> [<a href="https://doi.org/10.1212/wnl.39.9.1187" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2771070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Diamond%20SG,%20Markham%20CH,%20Hoehn%20MM,%20McDowell%20FH,%20Muenter%20MD.%20Effect%20of%20age%20at%20onset%20on%20progression%20and%20mortality%20in%20Parkinson%E2%80%99s%20disease.%20Neurology.%201989;39:1187%E2%80%9390." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology. 2005;65:1436–41.
</cite> [<a href="https://doi.org/10.1212/01.wnl.0000183359.50822.f2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16275832/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alves%20G,%20Wentzel-Larsen%20T,%20Aarsland%20D,%20Larsen%20JP.%20Progression%20of%20motor%20impairment%20and%20disability%20in%20Parkinson%20disease:%20a%20population-based%20study.%20Neurology.%202005;65:1436%E2%80%9341." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20:8661–72.
</cite> [<a href="https://doi.org/10.1002/alz.14313" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11667504/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39445596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20W,%20Wang%20Q,%20Qi%20X,%20Gurney%20M,%20Perry%20G,%20Volkow%20ND,%20Davis%20PB,%20Kaelber%20DC,%20Xu%20R.%20Associations%20of%20semaglutide%20with%20first-time%20diagnosis%20of%20Alzheimer%E2%80%99s%20disease%20in%20patients%20with%20type%202%20diabetes:%20target%20trial%20emulation%20using%20nationwide%20real-world%20data%20in%20the%20US.%20Alzheimers%20Dement.%202024;20:8661%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Maiti R, Mishra A, Jena M, Maji S, Padhan M, Mishra BR. Efficacy and safety of dasotraline in attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Indian J Psychiatry. 2024;66:326–35.
</cite> [<a href="https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_3_24" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11107928/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38778858/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maiti%20R,%20Mishra%20A,%20Jena%20M,%20Maji%20S,%20Padhan%20M,%20Mishra%20BR.%20Efficacy%20and%20safety%20of%20dasotraline%20in%20attention-deficit%20hyperactivity%20disorder:%20a%20systematic%20review%20and%20meta-analysis.%20Indian%20J%20Psychiatry.%202024;66:326%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data is provided within the manuscript.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Diabetology &amp; Metabolic Syndrome are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s13098-025-01888-1"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/13098_2025_Article_1888.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (5.8 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374370/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374370/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374370%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374370/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374370/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374370/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40849485/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374370/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40849485/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374370/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374370/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="kgay6mCy46xHjql4wGY1m1Fe6jtemO0ettrwVYBCgYuKLcK3Fm6b3oiAWgD1ltM6">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
